<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-1877 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-1877</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-1877</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-36.html">extraction-schema-36</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of systems that use computational or proxy metrics to make predictions or discoveries, and how those predictions compare to experimental or ground-truth validation results.</div>
                <p><strong>Paper ID:</strong> paper-278357574</p>
                <p><strong>Paper Title:</strong> From Patterns to Pills: How Informatics Is Shaping Medicinal Chemistry</p>
                <p><strong>Paper Abstract:</strong> In today’s information-driven era, machine learning is revolutionizing medicinal chemistry, offering a paradigm shift from traditional, intuition-based, and often bias-prone methods to the prediction of chemical properties without prior knowledge of the basic principles governing drug function. This perspective highlights the growing importance of informatics in shaping the field of medicinal chemistry, particularly through the concept of the “informacophore”. The informacophore refers to the minimal chemical structure, combined with computed molecular descriptors, fingerprints, and machine-learned representations of its structure, that are essential for a molecule to exhibit biological activity. Similar to a skeleton key unlocking multiple locks, the informacophore points to the molecular features that trigger biological responses. By identifying and optimizing informacophores through in-depth analysis of ultra-large datasets of potential lead compounds and automating standard parts in the development process, there will be a significant reduction in biased intuitive decisions, which may lead to systemic errors and a parallel acceleration of drug discovery processes.</p>
                <p><strong>Cost:</strong> 0.025</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e1877.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e1877.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of systems that use computational or proxy metrics to make predictions or discoveries, and how those predictions compare to experimental or ground-truth validation results.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Insilico Mpro design</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Insilico Medicine generative design of SARS-CoV-2 main protease (Mpro) inhibitors</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Generative deep-learning models used to design novel small-molecule inhibitors of SARS-CoV-2 Mpro; AI-designed leads were synthesized and reported to show nanomolar inhibitory activity upon experimental testing.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Potential 2019-nCoV 3C-like protease inhibitors designed using generative deep learning approaches.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>system_name</strong></td>
                            <td>Insilico Medicine generative deep learning pipeline</td>
                        </tr>
                        <tr>
                            <td><strong>domain</strong></td>
                            <td>drug discovery / antiviral therapeutics</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_name</strong></td>
                            <td>model-generated predicted activity score / generative model objective (likelihood of Mpro inhibition)</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_type</strong></td>
                            <td>data-driven ML model (generative deep learning)</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_description</strong></td>
                            <td>Generative deep-learning models producing candidate molecular structures conditioned on desired properties (predicted binding or activity against Mpro). Candidates ranked by internal scoring functions or surrogate predictors trained on bioactivity/binding data.</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_metric_name</strong></td>
                            <td>experimental inhibitory potency (enzyme inhibition assays; reported nanomolar IC50)</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_validation_method</strong></td>
                            <td>wet-lab synthesis of AI-designed compounds followed by biochemical enzymatic inhibition assays and pharmacological profiling (in vitro IC50 measurements, some pharmacological characterization reported)</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_performance</strong></td>
                            <td>reported nanomolar inhibitory activity for synthesized lead(s) (qualitative; IC50 in nanomolar range mentioned in the cited Insilico preprint)</td>
                        </tr>
                        <tr>
                            <td><strong>explicit_gap_measurement</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>false_positive_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>false_negative_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>has_both_proxy_and_ground_truth</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>validation_performed</strong></td>
                            <td>computational + experimental synthesis and biochemical assays</td>
                        </tr>
                        <tr>
                            <td><strong>number_predictions_made</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>number_experimentally_validated</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>discovery_novelty</strong></td>
                            <td>novel</td>
                        </tr>
                        <tr>
                            <td><strong>extrapolation_distance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction_method</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>validation_cost_time</strong></td>
                            <td>Not quantified in paper; authors note end-to-end acceleration but no explicit cost/time numbers given</td>
                        </tr>
                        <tr>
                            <td><strong>domain_maturity</strong></td>
                            <td>emerging ML methods applied end-to-end; experimental validation essential</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_failure_modes</strong></td>
                            <td>paper emphasizes generative models may propose synthetically infeasible or chemically implausible molecules (general limitation), but specific failure cases for this study not detailed</td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_quantification</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_calibration</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>multiple_proxy_types</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>validation_cascade</strong></td>
                            <td>computational generation → synthesis → in vitro enzymatic assays (Mpro) → further pharmacological profiling</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_baseline</strong></td>
                            <td>paper frames as accelerated vs traditional hit discovery but provides no quantitative head-to-head baseline comparison</td>
                        </tr>
                        <tr>
                            <td><strong>domain_specific_factors</strong></td>
                            <td>biochemical assay complexity, synthetic feasibility, biochemical vs. cellular translation</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e1877.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e1877.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of systems that use computational or proxy metrics to make predictions or discoveries, and how those predictions compare to experimental or ground-truth validation results.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Halicin (Stokes et al.)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neural-network-driven discovery of the antibiotic halicin</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A neural network trained on molecules with known antibacterial properties identified halicin, a molecule not previously used as an antibiotic; subsequent biological assays validated broad-spectrum activity including in vitro and in vivo efficacy against multidrug-resistant strains.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>A deep learning approach to antibiotic discovery.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>system_name</strong></td>
                            <td>Neural network antibiotic discovery pipeline (Stokes et al.)</td>
                        </tr>
                        <tr>
                            <td><strong>domain</strong></td>
                            <td>antibiotic discovery / microbiology</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_name</strong></td>
                            <td>predicted antibacterial activity score from neural network classifier/regressor</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_type</strong></td>
                            <td>data-driven ML model (neural network)</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_description</strong></td>
                            <td>Model trained on dataset of molecules labeled for antibacterial activity to predict probability or potency against bacterial targets; candidates selected from chemical libraries based on predicted scores.</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_metric_name</strong></td>
                            <td>experimental antibacterial activity (in vitro MIC values, in vivo efficacy in animal infection models)</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_validation_method</strong></td>
                            <td>in vitro bacterial growth inhibition assays (e.g., MIC determinations) and in vivo infection models to test efficacy against multidrug-resistant pathogens</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_performance</strong></td>
                            <td>experimental confirmation of broad-spectrum antibacterial activity for halicin in vitro and efficacy in in vivo models (qualitative; specific MIC values and in vivo results reported in original Stokes et al. paper but not reproduced numerically in this perspective)</td>
                        </tr>
                        <tr>
                            <td><strong>explicit_gap_measurement</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>false_positive_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>false_negative_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>has_both_proxy_and_ground_truth</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>validation_performed</strong></td>
                            <td>computational + experimental (in vitro and in vivo) validation</td>
                        </tr>
                        <tr>
                            <td><strong>number_predictions_made</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>number_experimentally_validated</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>discovery_novelty</strong></td>
                            <td>novel (outside conventional antibiotic chemical space)</td>
                        </tr>
                        <tr>
                            <td><strong>extrapolation_distance</strong></td>
                            <td>characterized as outside typical 'bio-like' antibiotic scaffolds (i.e., extrapolative from training set)</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction_method</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>validation_cost_time</strong></td>
                            <td>Not quantified in this perspective; original study included standard microbiology and animal model costs</td>
                        </tr>
                        <tr>
                            <td><strong>domain_maturity</strong></td>
                            <td>emerging; ML has shown capacity to discover novel scaffolds but requires biological validation</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_failure_modes</strong></td>
                            <td>general caveat: ML may prioritize molecules that are synthetically infeasible or biologically irrelevant; not all high-scoring molecules translate to in vivo efficacy</td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_quantification</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_calibration</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>multiple_proxy_types</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>validation_cascade</strong></td>
                            <td>computational prediction → in vitro antibacterial assays → in vivo infection models</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_baseline</strong></td>
                            <td>demonstrated discovery of chemically novel antibiotic that would likely have been missed by human heuristics; no quantitative comparison to human-led screens provided in perspective</td>
                        </tr>
                        <tr>
                            <td><strong>domain_specific_factors</strong></td>
                            <td>bacterial physiology, penetration/permeability, in vivo pharmacokinetics, resistance mechanisms</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e1877.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e1877.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of systems that use computational or proxy metrics to make predictions or discoveries, and how those predictions compare to experimental or ground-truth validation results.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>BenevolentAI baricitinib</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>BenevolentAI machine-learning identification of baricitinib for COVID-19 repurposing</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>BenevolentAI's ML pipeline flagged the approved JAK inhibitor baricitinib as a candidate for COVID-19 therapy; subsequent in vitro and clinical studies supported antiviral and anti-inflammatory effects, contributing to emergency use authorization.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>system_name</strong></td>
                            <td>BenevolentAI ML repurposing platform</td>
                        </tr>
                        <tr>
                            <td><strong>domain</strong></td>
                            <td>drug repurposing / clinical therapeutics</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_name</strong></td>
                            <td>inferred drug–disease relevance score (systems biology/ML-based ranking for repurposing)</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_type</strong></td>
                            <td>hybrid data-driven systems biology/ML (network-based inference)</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_description</strong></td>
                            <td>Systems-biology-informed ML that integrates protein interaction maps, pathway data, and existing drug-target information to score existing drugs for potential efficacy against new disease mechanisms (e.g., SARS-CoV-2).</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_metric_name</strong></td>
                            <td>experimental antiviral/clinical efficacy (in vitro antiviral assays, clinical trial outcomes)</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_validation_method</strong></td>
                            <td>in vitro antiviral assays to show antiviral or anti-inflammatory activity, followed by clinical evaluation (including emergency/compassionate use and clinical trials) to assess outcomes in patients</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_performance</strong></td>
                            <td>in vitro and clinical evidence supported baricitinib's antiviral/anti-inflammatory activity; resulted in regulatory emergency use authorization in specific contexts (qualitative outcome reported)</td>
                        </tr>
                        <tr>
                            <td><strong>explicit_gap_measurement</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>false_positive_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>false_negative_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>has_both_proxy_and_ground_truth</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>validation_performed</strong></td>
                            <td>computational + experimental (in vitro) + clinical validation</td>
                        </tr>
                        <tr>
                            <td><strong>number_predictions_made</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>number_experimentally_validated</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>discovery_novelty</strong></td>
                            <td>repurposing (not novel molecule but novel indication)</td>
                        </tr>
                        <tr>
                            <td><strong>extrapolation_distance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction_method</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>validation_cost_time</strong></td>
                            <td>Not quantified in perspective; clinical validation is substantially more costly/time-consuming than computational ranking</td>
                        </tr>
                        <tr>
                            <td><strong>domain_maturity</strong></td>
                            <td>systems-biology repurposing pipelines are established but rely on experimental validation for clinical translation</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_failure_modes</strong></td>
                            <td>risk of false positives that lack clinical efficacy; models may miss dosing/contextual factors</td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_quantification</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_calibration</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>multiple_proxy_types</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>validation_cascade</strong></td>
                            <td>computational systems-biology ranking → in vitro functional assays → clinical studies</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_baseline</strong></td>
                            <td>paper emphasizes computational prioritization accelerated repurposing but gives no numerical comparison to baseline discovery timelines</td>
                        </tr>
                        <tr>
                            <td><strong>domain_specific_factors</strong></td>
                            <td>disease complexity, host immune response, dosing/regimen differences, clinical heterogeneity</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e1877.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e1877.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of systems that use computational or proxy metrics to make predictions or discoveries, and how those predictions compare to experimental or ground-truth validation results.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Rufa hybrid ML/MM</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Hybrid physics-based machine learning / molecular mechanics potentials for alchemical free energy calculations (Rufa et al.)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A hybrid ML + molecular mechanics approach for binding free energy predictions reported to reduce RMSE nearly by half compared to conventional molecular mechanics alone, improving accuracy toward 'chemical accuracy' for alchemical free energy calculations.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Towards chemical accuracy for alchemical free energy calculations with hybrid physics-based machine learning/molecular mechanics potentials.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>system_name</strong></td>
                            <td>Hybrid ML/MM potential for alchemical free energy calculations</td>
                        </tr>
                        <tr>
                            <td><strong>domain</strong></td>
                            <td>computational chemistry / binding affinity prediction</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_name</strong></td>
                            <td>predicted binding free energy (ΔG) from hybrid ML/MM alchemical calculations</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_type</strong></td>
                            <td>hybrid approach (physics-based molecular mechanics combined with ML-corrected potentials)</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_description</strong></td>
                            <td>Alchemical free energy calculations where molecular mechanics potentials are augmented or corrected by machine-learned components to better approximate reference energies; predictions compared to reference binding free energies.</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_metric_name</strong></td>
                            <td>reference binding free energies (experimental or high-fidelity reference data)</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_validation_method</strong></td>
                            <td>comparison of predicted ΔG values to reference dataset (presumably experimental or high-fidelity computational reference) to compute RMSE</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_performance</strong></td>
                            <td>RMSE = 0.47 kcal·mol⁻¹ for binding free energy predictions (hybrid ML/MM)</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_performance</strong></td>
                            <td>conventional molecular mechanics RMSE = 0.97 kcal·mol⁻¹ on same test — hybrid approach nearly halves the error (values reported in cited preprint)</td>
                        </tr>
                        <tr>
                            <td><strong>explicit_gap_measurement</strong></td>
                            <td>error reduction from RMSE 0.97 to 0.47 kcal·mol⁻¹ when using hybrid ML/MM vs conventional MM (quantitative gap measurement reported)</td>
                        </tr>
                        <tr>
                            <td><strong>false_positive_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>false_negative_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>has_both_proxy_and_ground_truth</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>validation_performed</strong></td>
                            <td>computational comparison to reference dataset (likely experimental binding free energies or high-fidelity references); no in-lab synthesis/assay reported in this perspective's discussion</td>
                        </tr>
                        <tr>
                            <td><strong>number_predictions_made</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>number_experimentally_validated</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>discovery_novelty</strong></td>
                            <td>methodological improvement toward chemical accuracy</td>
                        </tr>
                        <tr>
                            <td><strong>extrapolation_distance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction_method</strong></td>
                            <td>machine-learned correction terms integrated with molecular mechanics potentials (hybrid ML/MM) to reduce systematic error of MM</td>
                        </tr>
                        <tr>
                            <td><strong>validation_cost_time</strong></td>
                            <td>paper notes conventional QM-level accuracy is costly; hybrid approach aimed to reduce computational expense, but specific cost/time trade-offs not quantified here</td>
                        </tr>
                        <tr>
                            <td><strong>domain_maturity</strong></td>
                            <td>advancing toward chemical accuracy; hybrid physics-ML models are emerging</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_failure_modes</strong></td>
                            <td>general caveat: ML corrections may not generalize beyond training chemical space; potential overfitting to reference set</td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_quantification</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_calibration</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>multiple_proxy_types</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>validation_cascade</strong></td>
                            <td>computational-only benchmarking vs reference dataset</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_baseline</strong></td>
                            <td>quantitative improvement over conventional MM (RMSE reduced from 0.97 to 0.47 kcal·mol⁻¹)</td>
                        </tr>
                        <tr>
                            <td><strong>domain_specific_factors</strong></td>
                            <td>sensitivity to force-field quality, sampling convergence, and chemical space represented in training data</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e1877.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e1877.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of systems that use computational or proxy metrics to make predictions or discoveries, and how those predictions compare to experimental or ground-truth validation results.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Chemprop logP model</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Chemprop message-passing neural network for QM-based approximation of drug lipophilicity (Lewis et al.)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A message-passing neural network (Chemprop) trained on public and Novartis in-house datasets to approximate quantum-mechanics-calculated log P (lipophilicity) values with high throughput and lower computational cost than QM calculations.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Machine intelligence models for fast, quantum mechanics-based approximation of drug lipophilicity.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>system_name</strong></td>
                            <td>Chemprop message-passing neural network for logP prediction</td>
                        </tr>
                        <tr>
                            <td><strong>domain</strong></td>
                            <td>ADMET prediction / cheminformatics</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_name</strong></td>
                            <td>predicted log P (octanol–water partition coefficient) from Chemprop ML model</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_type</strong></td>
                            <td>data-driven ML model trained to emulate quantum-mechanics calculations</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_description</strong></td>
                            <td>Chemprop message-passing neural network trained on a combination of public and proprietary QM-calculated lipophilicity values to predict QM-like log P values rapidly (hundreds of compounds per second).</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_metric_name</strong></td>
                            <td>quantum-mechanics computed log P values (used as reference ground-truth for training/testing)</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_validation_method</strong></td>
                            <td>scaffold-split test sets comparing Chemprop predictions to QM-calculated log P values (computational ground-truth), reported MAE on test sets</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_performance</strong></td>
                            <td>MAE = 0.44 log units (public dataset scaffold-split test set); MAE = 0.34 log units (Novartis in-house scaffold-split test set)</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_performance</strong></td>
                            <td>QM calculations are treated as reference; Chemprop approximates QM values with reported MAEs above</td>
                        </tr>
                        <tr>
                            <td><strong>explicit_gap_measurement</strong></td>
                            <td>MAE relative to QM reference: 0.34–0.44 log units (quantitative measure of proxy-to-reference gap)</td>
                        </tr>
                        <tr>
                            <td><strong>false_positive_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>false_negative_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>has_both_proxy_and_ground_truth</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>validation_performed</strong></td>
                            <td>computational benchmarking against QM-calculated reference datasets (no wet-lab log P experimental validation reported in perspective)</td>
                        </tr>
                        <tr>
                            <td><strong>number_predictions_made</strong></td>
                            <td>capable of hundreds of compounds per second (model throughput stated), but number of specific predictions in study not provided here</td>
                        </tr>
                        <tr>
                            <td><strong>number_experimentally_validated</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>discovery_novelty</strong></td>
                            <td>incremental methodological improvement (faster QM-like predictions)</td>
                        </tr>
                        <tr>
                            <td><strong>extrapolation_distance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction_method</strong></td>
                            <td>training ML model directly on QM outputs to reproduce QM-level predictions (data-driven emulation of higher-fidelity computation)</td>
                        </tr>
                        <tr>
                            <td><strong>validation_cost_time</strong></td>
                            <td>QM single-compound cost ~1 hour per compound vs Chemprop hundreds of compounds per second (presented qualitatively; no monetary cost provided)</td>
                        </tr>
                        <tr>
                            <td><strong>domain_maturity</strong></td>
                            <td>emerging practical ML emulators of QM-level descriptors</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_failure_modes</strong></td>
                            <td>performance depends on representativeness of training data; may perform worse out-of-distribution</td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_quantification</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_calibration</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>multiple_proxy_types</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>validation_cascade</strong></td>
                            <td>ML model trained on QM outputs → computational test on scaffold-split sets; intended as pre-screen before full QM calculations</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_baseline</strong></td>
                            <td>outperforms traditional regression models on scaffold-split tests (MAE quoted vs baselines in cited study), but no direct wet-lab comparison provided</td>
                        </tr>
                        <tr>
                            <td><strong>domain_specific_factors</strong></td>
                            <td>sensitivity to scaffold splits and data diversity; QM vs experimental measurement differences for log P</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e1877.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e1877.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of systems that use computational or proxy metrics to make predictions or discoveries, and how those predictions compare to experimental or ground-truth validation results.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Lyu ultra-large docking</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Ultra-large library molecular docking campaigns (Lyu et al.)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Ultra-large virtual screening (docking) of tangible libraries (billions of make-on-demand molecules) showing docking score improvements with library size and yielding thousands of high-ranking molecules, some experimentally active despite being dissimilar to bio-like molecules.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Modeling the expansion of virtual screening libraries.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>system_name</strong></td>
                            <td>Ultra-large-scale molecular docking pipeline</td>
                        </tr>
                        <tr>
                            <td><strong>domain</strong></td>
                            <td>virtual screening / structure-based drug discovery</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_name</strong></td>
                            <td>docking score / predicted binding affinity (docking-based ranking)</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_type</strong></td>
                            <td>physics-based simulation (molecular docking) with empirical scoring functions</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_description</strong></td>
                            <td>High-throughput docking of ultra-large virtual libraries into target binding sites using docking engines and scoring functions; molecules ranked by docking score as proxy for binding potency.</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_metric_name</strong></td>
                            <td>experimental bioactivity (assay-confirmed inhibitors identified from top-ranked docked molecules)</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_validation_method</strong></td>
                            <td>experimental testing of selected top-ranking docked compounds in biochemical or cellular assays to confirm activity</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_performance</strong></td>
                            <td>observed improvement of docking scores in a log-linear fashion with increasing library size; thousands of high-ranking candidates identified in campaigns</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_performance</strong></td>
                            <td>some top-ranking molecules were experimentally active (including inhibitors) — qualitative confirmation that docking can identify actives from ultra-large libraries; exact hit rates not given in perspective</td>
                        </tr>
                        <tr>
                            <td><strong>explicit_gap_measurement</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>false_positive_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>false_negative_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>has_both_proxy_and_ground_truth</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>validation_performed</strong></td>
                            <td>computational docking of ultra-large libraries + experimental testing of selected top-ranked candidates</td>
                        </tr>
                        <tr>
                            <td><strong>number_predictions_made</strong></td>
                            <td>docking campaigns across ultra-large libraries (billions of virtual compounds considered in principle; five campaigns studied per cited work)</td>
                        </tr>
                        <tr>
                            <td><strong>number_experimentally_validated</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>discovery_novelty</strong></td>
                            <td>novel candidates often dissimilar to bio-like molecules (outside typical heuristics)</td>
                        </tr>
                        <tr>
                            <td><strong>extrapolation_distance</strong></td>
                            <td>predicted candidates often far from bio-like training biases (i.e., extrapolative into non-biogenic chemical space)</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction_method</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>validation_cost_time</strong></td>
                            <td>computational screening of billions is computationally expensive; experimental validation required for only a tiny fraction (cost/time not numerically specified)</td>
                        </tr>
                        <tr>
                            <td><strong>domain_maturity</strong></td>
                            <td>well-established docking methods applied at unprecedented scale; experimental validation remains essential</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_failure_modes</strong></td>
                            <td>docking scoring functions can produce false positives and are sensitive to conformational sampling and scoring inaccuracies; docking bias toward shapes fitting scoring function rather than true activity</td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_quantification</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_calibration</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>multiple_proxy_types</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>validation_cascade</strong></td>
                            <td>ultra-large docking → selection of top-ranked candidates → experimental assays</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_baseline</strong></td>
                            <td>found actives that medicinal chemists would not have suggested due to dissimilarity to bio-like molecules; no numerical baseline comparison provided</td>
                        </tr>
                        <tr>
                            <td><strong>domain_specific_factors</strong></td>
                            <td>protein flexibility, solvation and entropic contributions not fully captured by docking scoring functions</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e1877.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e1877.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of systems that use computational or proxy metrics to make predictions or discoveries, and how those predictions compare to experimental or ground-truth validation results.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Akabayov RNA ML+NMR</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Akabayov group pipeline combining molecular descriptors, ML, and NMR fragment screening for RNA-targeted ligands</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Integrated approach using chemically interpretable descriptors, image-based CNN features, and classical ML methods to predict small-molecule binding to RNA; fragment hits were identified by NMR T2 relaxation screening and optimized via a computational hit-to-lead workflow followed by experimental biophysical validation.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Machine learning approaches to optimize small-molecule inhibitors for RNA targeting.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>system_name</strong></td>
                            <td>Descriptor + CNN + ML predictive pipeline coupled to NMR fragment screening</td>
                        </tr>
                        <tr>
                            <td><strong>domain</strong></td>
                            <td>RNA-targeted small-molecule discovery / chemical biology</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_name</strong></td>
                            <td>predicted molecule–RNA binding affinity / classification of binders (ML-predicted scores)</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_type</strong></td>
                            <td>hybrid (data-driven ML using chemically defined descriptors and CNN-derived visual features)</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_description</strong></td>
                            <td>Models trained on descriptors (solubility, counts of functional groups, molecular regularity) and CNN-extracted visual features from molecular images to predict binding to RNA targets; Lasso regression, decision trees, and CNN classifiers/regressors were explored.</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_metric_name</strong></td>
                            <td>biophysical binding evidence (NMR T2 relaxation fragment screening, subsequent biophysical assays for optimized compounds)</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_validation_method</strong></td>
                            <td>NMR T2 relaxation fragment screening to detect hits; hit-to-lead compounds synthesized/optimized and validated by biophysical assays measuring binding specificity and strength</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_performance</strong></td>
                            <td>fragment hit identified by NMR; computational optimization reportedly improved specificity and binding strength (qualitative; no numeric binding constants provided in perspective)</td>
                        </tr>
                        <tr>
                            <td><strong>explicit_gap_measurement</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>false_positive_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>false_negative_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>has_both_proxy_and_ground_truth</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>validation_performed</strong></td>
                            <td>computational modelling + NMR fragment screening + hit-to-lead synthesis and biophysical validation</td>
                        </tr>
                        <tr>
                            <td><strong>number_predictions_made</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>number_experimentally_validated</strong></td>
                            <td>at least one fragment scaffold hit validated by NMR and advanced through hit-to-lead (exact counts not provided)</td>
                        </tr>
                        <tr>
                            <td><strong>discovery_novelty</strong></td>
                            <td>incremental/targeted (starting from fragment scaffold toward optimized ligands)</td>
                        </tr>
                        <tr>
                            <td><strong>extrapolation_distance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction_method</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>validation_cost_time</strong></td>
                            <td>Not quantified; NMR fragment screening used as sensitive biophysical validation for weak binders</td>
                        </tr>
                        <tr>
                            <td><strong>domain_maturity</strong></td>
                            <td>combination of established biophysical fragment screening with emerging ML approaches for RNA targeting</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_failure_modes</strong></td>
                            <td>CNN-derived visual features can be less chemically interpretable; models may miss chemical context without descriptor anchoring</td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_quantification</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_calibration</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>multiple_proxy_types</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>validation_cascade</strong></td>
                            <td>computational modelling → NMR fragment screening → synthetic elaboration → biophysical validation</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_baseline</strong></td>
                            <td>approach intended to enhance detection of weak fragment binders and guide optimization vs traditional intuition; no quantitative baseline comparison provided</td>
                        </tr>
                        <tr>
                            <td><strong>domain_specific_factors</strong></td>
                            <td>weak fragment binding detection challenges, solubility issues, and fragment-to-lead synthetic complexity</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e1877.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e1877.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of systems that use computational or proxy metrics to make predictions or discoveries, and how those predictions compare to experimental or ground-truth validation results.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>MolFilterGAN / RAscore</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>MolFilterGAN triage and RAscore retrosynthetic accessibility scoring for AI-generated molecules</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Post-generation filters and ML classifiers that triage AI-designed molecules by synthetic feasibility and biological relevance (MolFilterGAN) and rapidly score synthesizability using ML-retrosynthesis (RAscore).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>MolFilterGAN: A progressively augmented generative adversarial network for triaging AI-designed molecules.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>system_name</strong></td>
                            <td>MolFilterGAN; RAscore</td>
                        </tr>
                        <tr>
                            <td><strong>domain</strong></td>
                            <td>generative chemistry / synthetic accessibility assessment</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_name</strong></td>
                            <td>synthetic accessibility score (SAS) / RAscore classifier output / MolFilterGAN triage score</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_type</strong></td>
                            <td>data-driven ML models (GAN-based triage, ML retrosynthesis classifier)</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_description</strong></td>
                            <td>MolFilterGAN uses adversarial training and progressive augmentation to rank generated molecules for plausibility and synthesizability; RAscore uses ML models trained on retrosynthesis planning outputs to rapidly classify synthesizability.</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_metric_name</strong></td>
                            <td>actual synthetic feasibility (success of retrosynthetic planning or laboratory synthesis)</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_validation_method</strong></td>
                            <td>comparison to retrosynthetic planning outputs and/or attempted synthesis in chemistry workflows (RAscore trained on retrosynthesis planner outputs; MolFilterGAN validated computationally and by downstream triage tasks)</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>explicit_gap_measurement</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>false_positive_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>false_negative_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>has_both_proxy_and_ground_truth</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>validation_performed</strong></td>
                            <td>computational benchmarking against retrosynthesis planners and datasets; some triage demonstrated in generative workflows but no systematic wet-lab synthesis validation reported in this perspective</td>
                        </tr>
                        <tr>
                            <td><strong>number_predictions_made</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>number_experimentally_validated</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>discovery_novelty</strong></td>
                            <td>methodological/tools for improving generative output quality</td>
                        </tr>
                        <tr>
                            <td><strong>extrapolation_distance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction_method</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>validation_cost_time</strong></td>
                            <td>RAscore designed to be rapid vs full retrosynthetic planning; exact costs not quantified</td>
                        </tr>
                        <tr>
                            <td><strong>domain_maturity</strong></td>
                            <td>emerging tooling to address synthetic feasibility bottleneck in generative chemistry</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_failure_modes</strong></td>
                            <td>may misclassify novel but synthesizable scaffolds as infeasible; reliant on retrosynthesis planner biases</td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_quantification</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_calibration</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>multiple_proxy_types</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>validation_cascade</strong></td>
                            <td>generative model → MolFilterGAN/RAscore triage → (optional) retrosynthesis planning → synthesis</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_baseline</strong></td>
                            <td>improves triage speed and integration vs manual assessment; no numerical performance metrics provided in this perspective</td>
                        </tr>
                        <tr>
                            <td><strong>domain_specific_factors</strong></td>
                            <td>availability and bias of reaction databases used to train retrosynthesis models; synthetic route complexity</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e1877.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e1877.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of systems that use computational or proxy metrics to make predictions or discoveries, and how those predictions compare to experimental or ground-truth validation results.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Menacer inverse-QSAR + docking</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Inverse-QSAR combined with molecular docking for de novo design of SARS-CoV-2 main protease inhibitors (Menacer et al.)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A methodology integrating inverse-QSAR with molecular docking to generate scaffold-based de novo inhibitors for SARS-CoV-2 Mpro, using reversible descriptors to maintain interpretability while optimizing predicted activity.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>New combined Inverse-QSAR and molecular docking method for scaffoldbased drug discovery.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>system_name</strong></td>
                            <td>Inverse-QSAR + docking de novo design pipeline</td>
                        </tr>
                        <tr>
                            <td><strong>domain</strong></td>
                            <td>inverse cheminformatics / drug design</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_name</strong></td>
                            <td>predicted activity from inverse-QSAR model and docking score (combined ranking)</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_type</strong></td>
                            <td>hybrid approach (data-driven inverse-QSAR + physics-based docking)</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_description</strong></td>
                            <td>Inverse-QSAR explores functional/property space to propose scaffolded structures predicted to meet activity descriptors; candidates further evaluated by molecular docking to assess binding-mode compatibility and scoring.</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_metric_name</strong></td>
                            <td>experimental activity (not reported in perspective)</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_validation_method</strong></td>
                            <td>not described in this perspective; approach reported as methodology for de novo generation with docking-based evaluation (likely computational validation only in cited work)</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>explicit_gap_measurement</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>false_positive_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>false_negative_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>has_both_proxy_and_ground_truth</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>validation_performed</strong></td>
                            <td>computational (inverse-QSAR + docking) — experimental follow-up not described here</td>
                        </tr>
                        <tr>
                            <td><strong>number_predictions_made</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>number_experimentally_validated</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>discovery_novelty</strong></td>
                            <td>novel scaffold-based structures (computationally generated)</td>
                        </tr>
                        <tr>
                            <td><strong>extrapolation_distance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction_method</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>validation_cost_time</strong></td>
                            <td>computational method intended to be tractable; no explicit cost/time numbers given</td>
                        </tr>
                        <tr>
                            <td><strong>domain_maturity</strong></td>
                            <td>inverse design methods established conceptually but experimental translation remains challenging</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_failure_modes</strong></td>
                            <td>generated molecules may be chemically implausible or synthetically inaccessible; docking/inverse-QSAR may not guarantee real bioactivity</td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_quantification</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_calibration</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>multiple_proxy_types</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>validation_cascade</strong></td>
                            <td>inverse-QSAR generation → docking evaluation → (experimental validation not reported in perspective)</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_baseline</strong></td>
                            <td>method aims to balance interpretability and predictive accuracy vs traditional inverse-QSAR approaches, but no quantitative baseline comparison provided here</td>
                        </tr>
                        <tr>
                            <td><strong>domain_specific_factors</strong></td>
                            <td>descriptor choice impacts interpretability and chemical plausibility; docking limitations as structural proxy</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e1877.9">
                <h3 class="extraction-instance">Extracted Data Instance 9 (e1877.9)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of systems that use computational or proxy metrics to make predictions or discoveries, and how those predictions compare to experimental or ground-truth validation results.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Vemurafenib in silico screen</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>In silico high-throughput screening identification of vemurafenib (BRAF inhibitor) with cellular validation</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>High-throughput in silico screening targeting BRAF (V600E) identified vemurafenib as a candidate; computational predictions were validated by cellular assays measuring ERK phosphorylation and tumor cell proliferation, informing SAR optimization.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>system_name</strong></td>
                            <td>High-throughput in silico screening targeting BRAF V600E</td>
                        </tr>
                        <tr>
                            <td><strong>domain</strong></td>
                            <td>oncology drug discovery / kinase inhibition</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_name</strong></td>
                            <td>docking/virtual screening scores targeting BRAF V600E</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_type</strong></td>
                            <td>physics-based docking / virtual screening</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_description</strong></td>
                            <td>In silico screening against the mutant BRAF kinase to rank candidate inhibitors by predicted binding and selectivity; top candidates progressed to cellular assays.</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_metric_name</strong></td>
                            <td>cell-based functional assays (ERK phosphorylation levels, tumor cell proliferation assays)</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_validation_method</strong></td>
                            <td>cellular assays measuring pathway readouts (ERK phosphorylation) and proliferation to confirm on-target biological effects and guide SAR</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_performance</strong></td>
                            <td>cellular assays validated predicted activity (reduction in ERK phosphorylation and tumor cell proliferation) leading to medicinal chemistry optimization and clinical development (qualitative)</td>
                        </tr>
                        <tr>
                            <td><strong>explicit_gap_measurement</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>false_positive_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>false_negative_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>has_both_proxy_and_ground_truth</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>validation_performed</strong></td>
                            <td>computational screening + cellular assay validation (in vitro)</td>
                        </tr>
                        <tr>
                            <td><strong>number_predictions_made</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>number_experimentally_validated</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>discovery_novelty</strong></td>
                            <td>therapeutic development from computational screening into clinical drug (historical success)</td>
                        </tr>
                        <tr>
                            <td><strong>extrapolation_distance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction_method</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>validation_cost_time</strong></td>
                            <td>not provided; screening reduced candidate space prior to cellular testing</td>
                        </tr>
                        <tr>
                            <td><strong>domain_maturity</strong></td>
                            <td>well-established structure-based screening used historically in kinase inhibitor discovery</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_failure_modes</strong></td>
                            <td>computational hits require cellular confirmation because docking does not capture cellular context, metabolism, or off-target effects</td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_quantification</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_calibration</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>multiple_proxy_types</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>validation_cascade</strong></td>
                            <td>in silico screening → cellular functional assays → SAR optimization → clinical development</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_baseline</strong></td>
                            <td>computational screening accelerated identification vs brute-force empirical screens, though detailed quantitative comparison not provided</td>
                        </tr>
                        <tr>
                            <td><strong>domain_specific_factors</strong></td>
                            <td>cellular signaling complexity, off-target kinase inhibition, pathway redundancy</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>A deep learning approach to antibiotic discovery. <em>(Rating: 2)</em></li>
                <li>Potential 2019-nCoV 3C-like protease inhibitors designed using generative deep learning approaches. <em>(Rating: 2)</em></li>
                <li>Towards chemical accuracy for alchemical free energy calculations with hybrid physics-based machine learning/molecular mechanics potentials. <em>(Rating: 2)</em></li>
                <li>Machine intelligence models for fast, quantum mechanics-based approximation of drug lipophilicity. <em>(Rating: 2)</em></li>
                <li>Modeling the expansion of virtual screening libraries. <em>(Rating: 2)</em></li>
                <li>New combined Inverse-QSAR and molecular docking method for scaffoldbased drug discovery. <em>(Rating: 2)</em></li>
                <li>MolFilterGAN: A progressively augmented generative adversarial network for triaging AI-designed molecules. <em>(Rating: 2)</em></li>
                <li>Machine learning approaches to optimize small-molecule inhibitors for RNA targeting. <em>(Rating: 2)</em></li>
            </ol>
        </div>

        <div class="section">
            <h2>Extracted Data (Debug)</h2>
            <pre><code>{
    "id": "extraction-result-1877",
    "paper_id": "paper-278357574",
    "extraction_schema_id": "extraction-schema-36",
    "extracted_data": [
        {
            "name_short": "Insilico Mpro design",
            "name_full": "Insilico Medicine generative design of SARS-CoV-2 main protease (Mpro) inhibitors",
            "brief_description": "Generative deep-learning models used to design novel small-molecule inhibitors of SARS-CoV-2 Mpro; AI-designed leads were synthesized and reported to show nanomolar inhibitory activity upon experimental testing.",
            "citation_title": "Potential 2019-nCoV 3C-like protease inhibitors designed using generative deep learning approaches.",
            "mention_or_use": "mention",
            "system_name": "Insilico Medicine generative deep learning pipeline",
            "domain": "drug discovery / antiviral therapeutics",
            "proxy_metric_name": "model-generated predicted activity score / generative model objective (likelihood of Mpro inhibition)",
            "proxy_metric_type": "data-driven ML model (generative deep learning)",
            "proxy_metric_description": "Generative deep-learning models producing candidate molecular structures conditioned on desired properties (predicted binding or activity against Mpro). Candidates ranked by internal scoring functions or surrogate predictors trained on bioactivity/binding data.",
            "ground_truth_metric_name": "experimental inhibitory potency (enzyme inhibition assays; reported nanomolar IC50)",
            "ground_truth_validation_method": "wet-lab synthesis of AI-designed compounds followed by biochemical enzymatic inhibition assays and pharmacological profiling (in vitro IC50 measurements, some pharmacological characterization reported)",
            "proxy_performance": null,
            "ground_truth_performance": "reported nanomolar inhibitory activity for synthesized lead(s) (qualitative; IC50 in nanomolar range mentioned in the cited Insilico preprint)",
            "explicit_gap_measurement": null,
            "false_positive_rate": null,
            "false_negative_rate": null,
            "has_both_proxy_and_ground_truth": true,
            "validation_performed": "computational + experimental synthesis and biochemical assays",
            "number_predictions_made": null,
            "number_experimentally_validated": null,
            "discovery_novelty": "novel",
            "extrapolation_distance": null,
            "proxy_bias_correction": null,
            "proxy_bias_correction_method": "",
            "validation_cost_time": "Not quantified in paper; authors note end-to-end acceleration but no explicit cost/time numbers given",
            "domain_maturity": "emerging ML methods applied end-to-end; experimental validation essential",
            "proxy_failure_modes": "paper emphasizes generative models may propose synthetically infeasible or chemically implausible molecules (general limitation), but specific failure cases for this study not detailed",
            "uncertainty_quantification": null,
            "uncertainty_calibration": "",
            "multiple_proxy_types": true,
            "validation_cascade": "computational generation → synthesis → in vitro enzymatic assays (Mpro) → further pharmacological profiling",
            "comparison_to_baseline": "paper frames as accelerated vs traditional hit discovery but provides no quantitative head-to-head baseline comparison",
            "domain_specific_factors": "biochemical assay complexity, synthetic feasibility, biochemical vs. cellular translation",
            "uuid": "e1877.0"
        },
        {
            "name_short": "Halicin (Stokes et al.)",
            "name_full": "Neural-network-driven discovery of the antibiotic halicin",
            "brief_description": "A neural network trained on molecules with known antibacterial properties identified halicin, a molecule not previously used as an antibiotic; subsequent biological assays validated broad-spectrum activity including in vitro and in vivo efficacy against multidrug-resistant strains.",
            "citation_title": "A deep learning approach to antibiotic discovery.",
            "mention_or_use": "mention",
            "system_name": "Neural network antibiotic discovery pipeline (Stokes et al.)",
            "domain": "antibiotic discovery / microbiology",
            "proxy_metric_name": "predicted antibacterial activity score from neural network classifier/regressor",
            "proxy_metric_type": "data-driven ML model (neural network)",
            "proxy_metric_description": "Model trained on dataset of molecules labeled for antibacterial activity to predict probability or potency against bacterial targets; candidates selected from chemical libraries based on predicted scores.",
            "ground_truth_metric_name": "experimental antibacterial activity (in vitro MIC values, in vivo efficacy in animal infection models)",
            "ground_truth_validation_method": "in vitro bacterial growth inhibition assays (e.g., MIC determinations) and in vivo infection models to test efficacy against multidrug-resistant pathogens",
            "proxy_performance": null,
            "ground_truth_performance": "experimental confirmation of broad-spectrum antibacterial activity for halicin in vitro and efficacy in in vivo models (qualitative; specific MIC values and in vivo results reported in original Stokes et al. paper but not reproduced numerically in this perspective)",
            "explicit_gap_measurement": null,
            "false_positive_rate": null,
            "false_negative_rate": null,
            "has_both_proxy_and_ground_truth": true,
            "validation_performed": "computational + experimental (in vitro and in vivo) validation",
            "number_predictions_made": null,
            "number_experimentally_validated": null,
            "discovery_novelty": "novel (outside conventional antibiotic chemical space)",
            "extrapolation_distance": "characterized as outside typical 'bio-like' antibiotic scaffolds (i.e., extrapolative from training set)",
            "proxy_bias_correction": null,
            "proxy_bias_correction_method": "",
            "validation_cost_time": "Not quantified in this perspective; original study included standard microbiology and animal model costs",
            "domain_maturity": "emerging; ML has shown capacity to discover novel scaffolds but requires biological validation",
            "proxy_failure_modes": "general caveat: ML may prioritize molecules that are synthetically infeasible or biologically irrelevant; not all high-scoring molecules translate to in vivo efficacy",
            "uncertainty_quantification": null,
            "uncertainty_calibration": "",
            "multiple_proxy_types": null,
            "validation_cascade": "computational prediction → in vitro antibacterial assays → in vivo infection models",
            "comparison_to_baseline": "demonstrated discovery of chemically novel antibiotic that would likely have been missed by human heuristics; no quantitative comparison to human-led screens provided in perspective",
            "domain_specific_factors": "bacterial physiology, penetration/permeability, in vivo pharmacokinetics, resistance mechanisms",
            "uuid": "e1877.1"
        },
        {
            "name_short": "BenevolentAI baricitinib",
            "name_full": "BenevolentAI machine-learning identification of baricitinib for COVID-19 repurposing",
            "brief_description": "BenevolentAI's ML pipeline flagged the approved JAK inhibitor baricitinib as a candidate for COVID-19 therapy; subsequent in vitro and clinical studies supported antiviral and anti-inflammatory effects, contributing to emergency use authorization.",
            "citation_title": "Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.",
            "mention_or_use": "mention",
            "system_name": "BenevolentAI ML repurposing platform",
            "domain": "drug repurposing / clinical therapeutics",
            "proxy_metric_name": "inferred drug–disease relevance score (systems biology/ML-based ranking for repurposing)",
            "proxy_metric_type": "hybrid data-driven systems biology/ML (network-based inference)",
            "proxy_metric_description": "Systems-biology-informed ML that integrates protein interaction maps, pathway data, and existing drug-target information to score existing drugs for potential efficacy against new disease mechanisms (e.g., SARS-CoV-2).",
            "ground_truth_metric_name": "experimental antiviral/clinical efficacy (in vitro antiviral assays, clinical trial outcomes)",
            "ground_truth_validation_method": "in vitro antiviral assays to show antiviral or anti-inflammatory activity, followed by clinical evaluation (including emergency/compassionate use and clinical trials) to assess outcomes in patients",
            "proxy_performance": null,
            "ground_truth_performance": "in vitro and clinical evidence supported baricitinib's antiviral/anti-inflammatory activity; resulted in regulatory emergency use authorization in specific contexts (qualitative outcome reported)",
            "explicit_gap_measurement": null,
            "false_positive_rate": null,
            "false_negative_rate": null,
            "has_both_proxy_and_ground_truth": true,
            "validation_performed": "computational + experimental (in vitro) + clinical validation",
            "number_predictions_made": null,
            "number_experimentally_validated": null,
            "discovery_novelty": "repurposing (not novel molecule but novel indication)",
            "extrapolation_distance": null,
            "proxy_bias_correction": null,
            "proxy_bias_correction_method": "",
            "validation_cost_time": "Not quantified in perspective; clinical validation is substantially more costly/time-consuming than computational ranking",
            "domain_maturity": "systems-biology repurposing pipelines are established but rely on experimental validation for clinical translation",
            "proxy_failure_modes": "risk of false positives that lack clinical efficacy; models may miss dosing/contextual factors",
            "uncertainty_quantification": null,
            "uncertainty_calibration": "",
            "multiple_proxy_types": true,
            "validation_cascade": "computational systems-biology ranking → in vitro functional assays → clinical studies",
            "comparison_to_baseline": "paper emphasizes computational prioritization accelerated repurposing but gives no numerical comparison to baseline discovery timelines",
            "domain_specific_factors": "disease complexity, host immune response, dosing/regimen differences, clinical heterogeneity",
            "uuid": "e1877.2"
        },
        {
            "name_short": "Rufa hybrid ML/MM",
            "name_full": "Hybrid physics-based machine learning / molecular mechanics potentials for alchemical free energy calculations (Rufa et al.)",
            "brief_description": "A hybrid ML + molecular mechanics approach for binding free energy predictions reported to reduce RMSE nearly by half compared to conventional molecular mechanics alone, improving accuracy toward 'chemical accuracy' for alchemical free energy calculations.",
            "citation_title": "Towards chemical accuracy for alchemical free energy calculations with hybrid physics-based machine learning/molecular mechanics potentials.",
            "mention_or_use": "mention",
            "system_name": "Hybrid ML/MM potential for alchemical free energy calculations",
            "domain": "computational chemistry / binding affinity prediction",
            "proxy_metric_name": "predicted binding free energy (ΔG) from hybrid ML/MM alchemical calculations",
            "proxy_metric_type": "hybrid approach (physics-based molecular mechanics combined with ML-corrected potentials)",
            "proxy_metric_description": "Alchemical free energy calculations where molecular mechanics potentials are augmented or corrected by machine-learned components to better approximate reference energies; predictions compared to reference binding free energies.",
            "ground_truth_metric_name": "reference binding free energies (experimental or high-fidelity reference data)",
            "ground_truth_validation_method": "comparison of predicted ΔG values to reference dataset (presumably experimental or high-fidelity computational reference) to compute RMSE",
            "proxy_performance": "RMSE = 0.47 kcal·mol⁻¹ for binding free energy predictions (hybrid ML/MM)",
            "ground_truth_performance": "conventional molecular mechanics RMSE = 0.97 kcal·mol⁻¹ on same test — hybrid approach nearly halves the error (values reported in cited preprint)",
            "explicit_gap_measurement": "error reduction from RMSE 0.97 to 0.47 kcal·mol⁻¹ when using hybrid ML/MM vs conventional MM (quantitative gap measurement reported)",
            "false_positive_rate": null,
            "false_negative_rate": null,
            "has_both_proxy_and_ground_truth": true,
            "validation_performed": "computational comparison to reference dataset (likely experimental binding free energies or high-fidelity references); no in-lab synthesis/assay reported in this perspective's discussion",
            "number_predictions_made": null,
            "number_experimentally_validated": null,
            "discovery_novelty": "methodological improvement toward chemical accuracy",
            "extrapolation_distance": null,
            "proxy_bias_correction": true,
            "proxy_bias_correction_method": "machine-learned correction terms integrated with molecular mechanics potentials (hybrid ML/MM) to reduce systematic error of MM",
            "validation_cost_time": "paper notes conventional QM-level accuracy is costly; hybrid approach aimed to reduce computational expense, but specific cost/time trade-offs not quantified here",
            "domain_maturity": "advancing toward chemical accuracy; hybrid physics-ML models are emerging",
            "proxy_failure_modes": "general caveat: ML corrections may not generalize beyond training chemical space; potential overfitting to reference set",
            "uncertainty_quantification": null,
            "uncertainty_calibration": "",
            "multiple_proxy_types": true,
            "validation_cascade": "computational-only benchmarking vs reference dataset",
            "comparison_to_baseline": "quantitative improvement over conventional MM (RMSE reduced from 0.97 to 0.47 kcal·mol⁻¹)",
            "domain_specific_factors": "sensitivity to force-field quality, sampling convergence, and chemical space represented in training data",
            "uuid": "e1877.3"
        },
        {
            "name_short": "Chemprop logP model",
            "name_full": "Chemprop message-passing neural network for QM-based approximation of drug lipophilicity (Lewis et al.)",
            "brief_description": "A message-passing neural network (Chemprop) trained on public and Novartis in-house datasets to approximate quantum-mechanics-calculated log P (lipophilicity) values with high throughput and lower computational cost than QM calculations.",
            "citation_title": "Machine intelligence models for fast, quantum mechanics-based approximation of drug lipophilicity.",
            "mention_or_use": "mention",
            "system_name": "Chemprop message-passing neural network for logP prediction",
            "domain": "ADMET prediction / cheminformatics",
            "proxy_metric_name": "predicted log P (octanol–water partition coefficient) from Chemprop ML model",
            "proxy_metric_type": "data-driven ML model trained to emulate quantum-mechanics calculations",
            "proxy_metric_description": "Chemprop message-passing neural network trained on a combination of public and proprietary QM-calculated lipophilicity values to predict QM-like log P values rapidly (hundreds of compounds per second).",
            "ground_truth_metric_name": "quantum-mechanics computed log P values (used as reference ground-truth for training/testing)",
            "ground_truth_validation_method": "scaffold-split test sets comparing Chemprop predictions to QM-calculated log P values (computational ground-truth), reported MAE on test sets",
            "proxy_performance": "MAE = 0.44 log units (public dataset scaffold-split test set); MAE = 0.34 log units (Novartis in-house scaffold-split test set)",
            "ground_truth_performance": "QM calculations are treated as reference; Chemprop approximates QM values with reported MAEs above",
            "explicit_gap_measurement": "MAE relative to QM reference: 0.34–0.44 log units (quantitative measure of proxy-to-reference gap)",
            "false_positive_rate": null,
            "false_negative_rate": null,
            "has_both_proxy_and_ground_truth": true,
            "validation_performed": "computational benchmarking against QM-calculated reference datasets (no wet-lab log P experimental validation reported in perspective)",
            "number_predictions_made": "capable of hundreds of compounds per second (model throughput stated), but number of specific predictions in study not provided here",
            "number_experimentally_validated": null,
            "discovery_novelty": "incremental methodological improvement (faster QM-like predictions)",
            "extrapolation_distance": null,
            "proxy_bias_correction": true,
            "proxy_bias_correction_method": "training ML model directly on QM outputs to reproduce QM-level predictions (data-driven emulation of higher-fidelity computation)",
            "validation_cost_time": "QM single-compound cost ~1 hour per compound vs Chemprop hundreds of compounds per second (presented qualitatively; no monetary cost provided)",
            "domain_maturity": "emerging practical ML emulators of QM-level descriptors",
            "proxy_failure_modes": "performance depends on representativeness of training data; may perform worse out-of-distribution",
            "uncertainty_quantification": null,
            "uncertainty_calibration": "",
            "multiple_proxy_types": null,
            "validation_cascade": "ML model trained on QM outputs → computational test on scaffold-split sets; intended as pre-screen before full QM calculations",
            "comparison_to_baseline": "outperforms traditional regression models on scaffold-split tests (MAE quoted vs baselines in cited study), but no direct wet-lab comparison provided",
            "domain_specific_factors": "sensitivity to scaffold splits and data diversity; QM vs experimental measurement differences for log P",
            "uuid": "e1877.4"
        },
        {
            "name_short": "Lyu ultra-large docking",
            "name_full": "Ultra-large library molecular docking campaigns (Lyu et al.)",
            "brief_description": "Ultra-large virtual screening (docking) of tangible libraries (billions of make-on-demand molecules) showing docking score improvements with library size and yielding thousands of high-ranking molecules, some experimentally active despite being dissimilar to bio-like molecules.",
            "citation_title": "Modeling the expansion of virtual screening libraries.",
            "mention_or_use": "mention",
            "system_name": "Ultra-large-scale molecular docking pipeline",
            "domain": "virtual screening / structure-based drug discovery",
            "proxy_metric_name": "docking score / predicted binding affinity (docking-based ranking)",
            "proxy_metric_type": "physics-based simulation (molecular docking) with empirical scoring functions",
            "proxy_metric_description": "High-throughput docking of ultra-large virtual libraries into target binding sites using docking engines and scoring functions; molecules ranked by docking score as proxy for binding potency.",
            "ground_truth_metric_name": "experimental bioactivity (assay-confirmed inhibitors identified from top-ranked docked molecules)",
            "ground_truth_validation_method": "experimental testing of selected top-ranking docked compounds in biochemical or cellular assays to confirm activity",
            "proxy_performance": "observed improvement of docking scores in a log-linear fashion with increasing library size; thousands of high-ranking candidates identified in campaigns",
            "ground_truth_performance": "some top-ranking molecules were experimentally active (including inhibitors) — qualitative confirmation that docking can identify actives from ultra-large libraries; exact hit rates not given in perspective",
            "explicit_gap_measurement": null,
            "false_positive_rate": null,
            "false_negative_rate": null,
            "has_both_proxy_and_ground_truth": true,
            "validation_performed": "computational docking of ultra-large libraries + experimental testing of selected top-ranked candidates",
            "number_predictions_made": "docking campaigns across ultra-large libraries (billions of virtual compounds considered in principle; five campaigns studied per cited work)",
            "number_experimentally_validated": null,
            "discovery_novelty": "novel candidates often dissimilar to bio-like molecules (outside typical heuristics)",
            "extrapolation_distance": "predicted candidates often far from bio-like training biases (i.e., extrapolative into non-biogenic chemical space)",
            "proxy_bias_correction": false,
            "proxy_bias_correction_method": "",
            "validation_cost_time": "computational screening of billions is computationally expensive; experimental validation required for only a tiny fraction (cost/time not numerically specified)",
            "domain_maturity": "well-established docking methods applied at unprecedented scale; experimental validation remains essential",
            "proxy_failure_modes": "docking scoring functions can produce false positives and are sensitive to conformational sampling and scoring inaccuracies; docking bias toward shapes fitting scoring function rather than true activity",
            "uncertainty_quantification": null,
            "uncertainty_calibration": "",
            "multiple_proxy_types": null,
            "validation_cascade": "ultra-large docking → selection of top-ranked candidates → experimental assays",
            "comparison_to_baseline": "found actives that medicinal chemists would not have suggested due to dissimilarity to bio-like molecules; no numerical baseline comparison provided",
            "domain_specific_factors": "protein flexibility, solvation and entropic contributions not fully captured by docking scoring functions",
            "uuid": "e1877.5"
        },
        {
            "name_short": "Akabayov RNA ML+NMR",
            "name_full": "Akabayov group pipeline combining molecular descriptors, ML, and NMR fragment screening for RNA-targeted ligands",
            "brief_description": "Integrated approach using chemically interpretable descriptors, image-based CNN features, and classical ML methods to predict small-molecule binding to RNA; fragment hits were identified by NMR T2 relaxation screening and optimized via a computational hit-to-lead workflow followed by experimental biophysical validation.",
            "citation_title": "Machine learning approaches to optimize small-molecule inhibitors for RNA targeting.",
            "mention_or_use": "use",
            "system_name": "Descriptor + CNN + ML predictive pipeline coupled to NMR fragment screening",
            "domain": "RNA-targeted small-molecule discovery / chemical biology",
            "proxy_metric_name": "predicted molecule–RNA binding affinity / classification of binders (ML-predicted scores)",
            "proxy_metric_type": "hybrid (data-driven ML using chemically defined descriptors and CNN-derived visual features)",
            "proxy_metric_description": "Models trained on descriptors (solubility, counts of functional groups, molecular regularity) and CNN-extracted visual features from molecular images to predict binding to RNA targets; Lasso regression, decision trees, and CNN classifiers/regressors were explored.",
            "ground_truth_metric_name": "biophysical binding evidence (NMR T2 relaxation fragment screening, subsequent biophysical assays for optimized compounds)",
            "ground_truth_validation_method": "NMR T2 relaxation fragment screening to detect hits; hit-to-lead compounds synthesized/optimized and validated by biophysical assays measuring binding specificity and strength",
            "proxy_performance": null,
            "ground_truth_performance": "fragment hit identified by NMR; computational optimization reportedly improved specificity and binding strength (qualitative; no numeric binding constants provided in perspective)",
            "explicit_gap_measurement": null,
            "false_positive_rate": null,
            "false_negative_rate": null,
            "has_both_proxy_and_ground_truth": true,
            "validation_performed": "computational modelling + NMR fragment screening + hit-to-lead synthesis and biophysical validation",
            "number_predictions_made": null,
            "number_experimentally_validated": "at least one fragment scaffold hit validated by NMR and advanced through hit-to-lead (exact counts not provided)",
            "discovery_novelty": "incremental/targeted (starting from fragment scaffold toward optimized ligands)",
            "extrapolation_distance": null,
            "proxy_bias_correction": null,
            "proxy_bias_correction_method": "",
            "validation_cost_time": "Not quantified; NMR fragment screening used as sensitive biophysical validation for weak binders",
            "domain_maturity": "combination of established biophysical fragment screening with emerging ML approaches for RNA targeting",
            "proxy_failure_modes": "CNN-derived visual features can be less chemically interpretable; models may miss chemical context without descriptor anchoring",
            "uncertainty_quantification": null,
            "uncertainty_calibration": "",
            "multiple_proxy_types": true,
            "validation_cascade": "computational modelling → NMR fragment screening → synthetic elaboration → biophysical validation",
            "comparison_to_baseline": "approach intended to enhance detection of weak fragment binders and guide optimization vs traditional intuition; no quantitative baseline comparison provided",
            "domain_specific_factors": "weak fragment binding detection challenges, solubility issues, and fragment-to-lead synthetic complexity",
            "uuid": "e1877.6"
        },
        {
            "name_short": "MolFilterGAN / RAscore",
            "name_full": "MolFilterGAN triage and RAscore retrosynthetic accessibility scoring for AI-generated molecules",
            "brief_description": "Post-generation filters and ML classifiers that triage AI-designed molecules by synthetic feasibility and biological relevance (MolFilterGAN) and rapidly score synthesizability using ML-retrosynthesis (RAscore).",
            "citation_title": "MolFilterGAN: A progressively augmented generative adversarial network for triaging AI-designed molecules.",
            "mention_or_use": "mention",
            "system_name": "MolFilterGAN; RAscore",
            "domain": "generative chemistry / synthetic accessibility assessment",
            "proxy_metric_name": "synthetic accessibility score (SAS) / RAscore classifier output / MolFilterGAN triage score",
            "proxy_metric_type": "data-driven ML models (GAN-based triage, ML retrosynthesis classifier)",
            "proxy_metric_description": "MolFilterGAN uses adversarial training and progressive augmentation to rank generated molecules for plausibility and synthesizability; RAscore uses ML models trained on retrosynthesis planning outputs to rapidly classify synthesizability.",
            "ground_truth_metric_name": "actual synthetic feasibility (success of retrosynthetic planning or laboratory synthesis)",
            "ground_truth_validation_method": "comparison to retrosynthetic planning outputs and/or attempted synthesis in chemistry workflows (RAscore trained on retrosynthesis planner outputs; MolFilterGAN validated computationally and by downstream triage tasks)",
            "proxy_performance": null,
            "ground_truth_performance": null,
            "explicit_gap_measurement": null,
            "false_positive_rate": null,
            "false_negative_rate": null,
            "has_both_proxy_and_ground_truth": false,
            "validation_performed": "computational benchmarking against retrosynthesis planners and datasets; some triage demonstrated in generative workflows but no systematic wet-lab synthesis validation reported in this perspective",
            "number_predictions_made": null,
            "number_experimentally_validated": null,
            "discovery_novelty": "methodological/tools for improving generative output quality",
            "extrapolation_distance": null,
            "proxy_bias_correction": null,
            "proxy_bias_correction_method": "",
            "validation_cost_time": "RAscore designed to be rapid vs full retrosynthetic planning; exact costs not quantified",
            "domain_maturity": "emerging tooling to address synthetic feasibility bottleneck in generative chemistry",
            "proxy_failure_modes": "may misclassify novel but synthesizable scaffolds as infeasible; reliant on retrosynthesis planner biases",
            "uncertainty_quantification": null,
            "uncertainty_calibration": "",
            "multiple_proxy_types": null,
            "validation_cascade": "generative model → MolFilterGAN/RAscore triage → (optional) retrosynthesis planning → synthesis",
            "comparison_to_baseline": "improves triage speed and integration vs manual assessment; no numerical performance metrics provided in this perspective",
            "domain_specific_factors": "availability and bias of reaction databases used to train retrosynthesis models; synthetic route complexity",
            "uuid": "e1877.7"
        },
        {
            "name_short": "Menacer inverse-QSAR + docking",
            "name_full": "Inverse-QSAR combined with molecular docking for de novo design of SARS-CoV-2 main protease inhibitors (Menacer et al.)",
            "brief_description": "A methodology integrating inverse-QSAR with molecular docking to generate scaffold-based de novo inhibitors for SARS-CoV-2 Mpro, using reversible descriptors to maintain interpretability while optimizing predicted activity.",
            "citation_title": "New combined Inverse-QSAR and molecular docking method for scaffoldbased drug discovery.",
            "mention_or_use": "mention",
            "system_name": "Inverse-QSAR + docking de novo design pipeline",
            "domain": "inverse cheminformatics / drug design",
            "proxy_metric_name": "predicted activity from inverse-QSAR model and docking score (combined ranking)",
            "proxy_metric_type": "hybrid approach (data-driven inverse-QSAR + physics-based docking)",
            "proxy_metric_description": "Inverse-QSAR explores functional/property space to propose scaffolded structures predicted to meet activity descriptors; candidates further evaluated by molecular docking to assess binding-mode compatibility and scoring.",
            "ground_truth_metric_name": "experimental activity (not reported in perspective)",
            "ground_truth_validation_method": "not described in this perspective; approach reported as methodology for de novo generation with docking-based evaluation (likely computational validation only in cited work)",
            "proxy_performance": null,
            "ground_truth_performance": null,
            "explicit_gap_measurement": null,
            "false_positive_rate": null,
            "false_negative_rate": null,
            "has_both_proxy_and_ground_truth": false,
            "validation_performed": "computational (inverse-QSAR + docking) — experimental follow-up not described here",
            "number_predictions_made": null,
            "number_experimentally_validated": null,
            "discovery_novelty": "novel scaffold-based structures (computationally generated)",
            "extrapolation_distance": null,
            "proxy_bias_correction": null,
            "proxy_bias_correction_method": "",
            "validation_cost_time": "computational method intended to be tractable; no explicit cost/time numbers given",
            "domain_maturity": "inverse design methods established conceptually but experimental translation remains challenging",
            "proxy_failure_modes": "generated molecules may be chemically implausible or synthetically inaccessible; docking/inverse-QSAR may not guarantee real bioactivity",
            "uncertainty_quantification": null,
            "uncertainty_calibration": "",
            "multiple_proxy_types": true,
            "validation_cascade": "inverse-QSAR generation → docking evaluation → (experimental validation not reported in perspective)",
            "comparison_to_baseline": "method aims to balance interpretability and predictive accuracy vs traditional inverse-QSAR approaches, but no quantitative baseline comparison provided here",
            "domain_specific_factors": "descriptor choice impacts interpretability and chemical plausibility; docking limitations as structural proxy",
            "uuid": "e1877.8"
        },
        {
            "name_short": "Vemurafenib in silico screen",
            "name_full": "In silico high-throughput screening identification of vemurafenib (BRAF inhibitor) with cellular validation",
            "brief_description": "High-throughput in silico screening targeting BRAF (V600E) identified vemurafenib as a candidate; computational predictions were validated by cellular assays measuring ERK phosphorylation and tumor cell proliferation, informing SAR optimization.",
            "citation_title": "Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.",
            "mention_or_use": "mention",
            "system_name": "High-throughput in silico screening targeting BRAF V600E",
            "domain": "oncology drug discovery / kinase inhibition",
            "proxy_metric_name": "docking/virtual screening scores targeting BRAF V600E",
            "proxy_metric_type": "physics-based docking / virtual screening",
            "proxy_metric_description": "In silico screening against the mutant BRAF kinase to rank candidate inhibitors by predicted binding and selectivity; top candidates progressed to cellular assays.",
            "ground_truth_metric_name": "cell-based functional assays (ERK phosphorylation levels, tumor cell proliferation assays)",
            "ground_truth_validation_method": "cellular assays measuring pathway readouts (ERK phosphorylation) and proliferation to confirm on-target biological effects and guide SAR",
            "proxy_performance": null,
            "ground_truth_performance": "cellular assays validated predicted activity (reduction in ERK phosphorylation and tumor cell proliferation) leading to medicinal chemistry optimization and clinical development (qualitative)",
            "explicit_gap_measurement": null,
            "false_positive_rate": null,
            "false_negative_rate": null,
            "has_both_proxy_and_ground_truth": true,
            "validation_performed": "computational screening + cellular assay validation (in vitro)",
            "number_predictions_made": null,
            "number_experimentally_validated": null,
            "discovery_novelty": "therapeutic development from computational screening into clinical drug (historical success)",
            "extrapolation_distance": null,
            "proxy_bias_correction": null,
            "proxy_bias_correction_method": "",
            "validation_cost_time": "not provided; screening reduced candidate space prior to cellular testing",
            "domain_maturity": "well-established structure-based screening used historically in kinase inhibitor discovery",
            "proxy_failure_modes": "computational hits require cellular confirmation because docking does not capture cellular context, metabolism, or off-target effects",
            "uncertainty_quantification": null,
            "uncertainty_calibration": "",
            "multiple_proxy_types": null,
            "validation_cascade": "in silico screening → cellular functional assays → SAR optimization → clinical development",
            "comparison_to_baseline": "computational screening accelerated identification vs brute-force empirical screens, though detailed quantitative comparison not provided",
            "domain_specific_factors": "cellular signaling complexity, off-target kinase inhibition, pathway redundancy",
            "uuid": "e1877.9"
        }
    ],
    "potentially_relevant_new_papers": [
        {
            "paper_title": "A deep learning approach to antibiotic discovery.",
            "rating": 2
        },
        {
            "paper_title": "Potential 2019-nCoV 3C-like protease inhibitors designed using generative deep learning approaches.",
            "rating": 2
        },
        {
            "paper_title": "Towards chemical accuracy for alchemical free energy calculations with hybrid physics-based machine learning/molecular mechanics potentials.",
            "rating": 2
        },
        {
            "paper_title": "Machine intelligence models for fast, quantum mechanics-based approximation of drug lipophilicity.",
            "rating": 2
        },
        {
            "paper_title": "Modeling the expansion of virtual screening libraries.",
            "rating": 2
        },
        {
            "paper_title": "New combined Inverse-QSAR and molecular docking method for scaffoldbased drug discovery.",
            "rating": 2
        },
        {
            "paper_title": "MolFilterGAN: A progressively augmented generative adversarial network for triaging AI-designed molecules.",
            "rating": 2
        },
        {
            "paper_title": "Machine learning approaches to optimize small-molecule inhibitors for RNA targeting.",
            "rating": 2
        }
    ],
    "cost": 0.024749749999999997,
    "model_str": "gpt-5-mini"
}</code></pre>
        </div>
        <div class="section">
            <h2>Paper</h2>
            <div class="paper-content"><p>From Patterns to Pills: How Informatics Is Shaping Medicinal Chemistry
5 May 2025</p>
<p>Alexander Trachtenberg 
Department of Chemistry and Data Science Research Center
Ben-Gurion University of the Negev
8410501Beer-ShevaIsrael</p>
<p>Barak Akabayov akabayov@bgu.ac.il 0000-0002-3882-2742
Department of Chemistry and Data Science Research Center
Ben-Gurion University of the Negev
8410501Beer-ShevaIsrael</p>
<p>From Patterns to Pills: How Informatics Is Shaping Medicinal Chemistry
5 May 202552781F8559A8F68FF1634DA6BC6A743510.3390/pharmaceutics17050612Received: 20 March 2025 Revised: 25 April 2025 Accepted: 3 May 2025informacophoredrug discoveryinverse cheminformaticsmachine learningdata sciencemedicinal chemistry
In today's information-driven era, machine learning is revolutionizing medicinal chemistry, offering a paradigm shift from traditional, intuition-based, and often bias-prone methods to the prediction of chemical properties without prior knowledge of the basic principles governing drug function.This perspective highlights the growing importance of informatics in shaping the field of medicinal chemistry, particularly through the concept of the "informacophore".The informacophore refers to the minimal chemical structure, combined with computed molecular descriptors, fingerprints, and machine-learned representations of its structure, that are essential for a molecule to exhibit biological activity.Similar to a skeleton key unlocking multiple locks, the informacophore points to the molecular features that trigger biological responses.By identifying and optimizing informacophores through in-depth analysis of ultra-large datasets of potential lead compounds and automating standard parts in the development process, there will be a significant reduction in biased intuitive decisions, which may lead to systemic errors and a parallel acceleration of drug discovery processes.</p>
<p>Approaches to Drug Discovery and Development</p>
<p>Classical Drug Discovery</p>
<p>Classical drug discovery follows a structured pipeline of complex and time-consuming steps [1].The process begins with identifying a biological target, such as DNA, RNA, or a specific protein that plays a particular role in disease development.Thereafter, hit compounds are identified by screening molecules that can interact with the chosen biological target.After the identification of these hit compounds, their chemical structures and drug properties must be optimized to develop lead compounds.Completion of the hit-to-lead process is followed by the preclinical phase, during which the ADMET properties (absorption, distribution, metabolism, excretion, and toxicity), safety, and dosage of promising drug candidates are further evaluated both in vitro and in vivo.For successful candidates, the long process of clinical trials is then begun to evaluate drug safety and effectiveness in humans.</p>
<p>It has been estimated that the average cost of a classical drug discovery pipeline is USD 2.6 billion and that a complete traditional workflow can take over 12 years [2].Thus, to shorten discovery timelines, reduce development costs, and improve the odds of clinical success, computational-and artificial intelligence (AI)-based methods have been used to counter the high costs and lengthy timelines that constitute significant bottlenecks in drug development [3]. Figure 1 illustrates the classical drug discovery paradigm, highlighting five key steps in the pipeline: assay optimization, hit identification, hit-to-lead progression, ADMET analysis, and clinical approval.Each of these steps, in turn, narrows the chemical search space for potential drug candidates, as indicated by the varying sizes of the circles in the figure, where the larger the circle, the greater the chemical space.Each step includes an appropriate computer-aided drug design (CADD) method or combination of methods, which may incorporate informatics, modeling, simulation, and/or AI.For instance, the hit identification phase can be dramatically accelerated by implementing CADD methods, such as de novo design, molecular docking, pharmacophore modeling, and chemical similarity searches, to significantly enhance virtual screening or chemical data analysis processes [4].</p>
<p>to counter the high costs and lengthy timelines that constitute significant bottlenecks in drug development [3]. Figure 1 illustrates the classical drug discovery paradigm, highlighting five key steps in the pipeline: assay optimization, hit identification, hit-to-lead progression, ADMET analysis, and clinical approval.Each of these steps, in turn, narrows the chemical search space for potential drug candidates, as indicated by the varying sizes of the circles in the figure, where the larger the circle, the greater the chemical space.Each step includes an appropriate computer-aided drug design (CADD) method or combination of methods, which may incorporate informatics, modeling, simulation, and/or AI.For instance, the hit identification phase can be dramatically accelerated by implementing CADD methods, such as de novo design, molecular docking, pharmacophore modeling, and chemical similarity searches, to significantly enhance virtual screening or chemical data analysis processes [4].</p>
<p>The Role of Biological Functional Assays in Modern Drug Discovery</p>
<p>While computational tools and AI have revolutionized early-stage drug discovery by enabling rapid identification of potential drug candidates, these in silico approaches are only the starting point of a much broader experimental validation pipeline.Theoretical predictions-such as target binding affinities, selectivity, and potential off-target effectsmust be rigorously confirmed through biological functional assays like enzyme inhibition, cell viability, reporter gene expression, or pathway-specific readouts to establish realworld pharmacological relevance [5].These assays, conducted in vitro or in vivo, offer quantitative, empirical insights into compound behavior within biological systems.They also provide critical data on compound activity, potency, and mechanism of action, thereby acting as an indispensable bridge between computational hypotheses and therapeutic reality.These critical data and insights validate or challenge AI-generated predictions and provide feedback into structure-activity relationship (SAR) studies, guiding medicinal chemists to design analogues with improved efficacy, selectivity, and safety [6].This iterative feedback loop-spanning prediction, validation, and optimization-is central to the modern drug discovery process [7].</p>
<p>The Role of Biological Functional Assays in Modern Drug Discovery</p>
<p>While computational tools and AI have revolutionized early-stage drug discovery by enabling rapid identification of potential drug candidates, these in silico approaches are only the starting point of a much broader experimental validation pipeline.Theoretical predictions-such as target binding affinities, selectivity, and potential off-target effects-must be rigorously confirmed through biological functional assays like enzyme inhibition, cell viability, reporter gene expression, or pathway-specific readouts to establish real-world pharmacological relevance [5].These assays, conducted in vitro or in vivo, offer quantitative, empirical insights into compound behavior within biological systems.They also provide critical data on compound activity, potency, and mechanism of action, thereby acting as an indispensable bridge between computational hypotheses and therapeutic reality.These critical data and insights validate or challenge AI-generated predictions and provide feedback into structure-activity relationship (SAR) studies, guiding medicinal chemists to design analogues with improved efficacy, selectivity, and safety [6].This iterative feedback loop-spanning prediction, validation, and optimization-is central to the modern drug discovery process [7].</p>
<p>Advances in assay technologies have further strengthened this feedback mechanism.High-content screening, phenotypic assays, and organoid or 3D culture systems offer more physiologically relevant models that enhance translational relevance and better predict clinical success [8].In this context, biological functional assays are not just confirmatory Pharmaceutics 2025, 17, 612 3 of 17 tools but strategic enablers that shape the direction of both computational exploration and chemical design.This synergy is exemplified in several notable drug discovery case studies:</p>
<p>•</p>
<p>Baricitinib, a repurposed JAK inhibitor identified by BenevolentAI's machine learning (ML) algortihm as a candidate for COVID-19, required extensive in vitro and clinical validation to confirm its antiviral and anti-inflammatory effects, ultimately supporting its emergency use authorization [9].</p>
<p>•</p>
<p>Halicin, a novel antibiotic discovered using a neural network trained on a dataset of molecules with known antibacterial properties, enabling the model to identify compounds with potential activity against Escherichia coli.Although the compound's antibacterial potential was flagged computationally, biological assays were crucial to confirming its broad-spectrum efficacy, including activity against multidrug-resistant pathogens in both in vitro and in vivo models [10].</p>
<p>•</p>
<p>Capmatinib, initially developed as an oncology drug, was identified through systems biology and AI as a candidate for antiviral therapy.Its ability to disrupt coronavirus replication was validated through functional assays, highlighting its potential for drug repurposing [11,12].• Vemurafenib, a BRAF inhibitor for melanoma, was initially identified via high- throughput in silico screening targeting the BRAF (V600E)-mutant kinase.Its computational promise was validated through cellular assays measuring ERK phosphorylation and tumor cell proliferation [13], ultimately guiding SAR efforts to enhance potency and reduce off-target effects.</p>
<p>These cases underscore a fundamental principle in modern drug development: without biological functional assays, even the most promising computational leads remain hypothetical.Only through experimental validation is therapeutic potential confirmed, enabling medicinal chemists to make informed decisions in the iterative process of drug optimization.Biological assays thus form the empirical backbone of the discovery continuum, ensuring that AI-driven innovation translates into real-world medical advances.</p>
<p>Rational Drug Design in Scaffold-Centric Medicinal Chemistry</p>
<p>As computational and biological methods converge to identify promising lead compounds, refining these candidates into viable therapeutics is the next crucial step in the discovery pipeline.This refinement increasingly centers on the molecular scaffold-the minimal structure required for bioactivity-underscoring the importance of rational drug design (RDD).Traditionally, the pharmacophore has been used to represent the spatial arrangement of chemical features essential for molecular recognition by a biological target.While the pharmacophore is rooted in human-defined heuristics and chemical intuition, the informacophore extends this idea by incorporating data-driven insights derived not only from SARs, but also from computed molecular descriptors, fingerprints, and machinelearned representations of chemical structure.This fusion of structural chemistry with informatics enables a more systematic and bias-resistant strategy for scaffold modification and optimization.</p>
<p>Feeding the essential molecular features of the informacophore into complex ML models can offer greater predictive power, but also raises challenges of model interpretability.Unlike traditional pharmacophore models, which rely on human expertise, machinelearned informacophores can be challenging to interpret directly, with learned features often becoming opaque or harder to link back to specific chemical properties.Despite these challenges, hybrid methods-guided by medicinal chemists-are emerging to combine interpretable chemical descriptors with learned features from ML models [14,15].helping to bridge this interpretability gap.By grounding machine-learned insights in chemical intuition and data-driven patterns, informacophores can better understand how specific chemical features influence biological activity.Thus, they offer the potential to become a key element of modern RDD strategies, offering a more efficient and scalable path from discovery to commercialization than traditional intuition-led approaches [16].</p>
<p>RDD was first formalized in the 1950s, when it became possible for theoretical insights into drug-receptor interactions and hands-on drug testing to continuously reinforce one another, making RDD achievable [17].In the 1980s, RDD acquired the status of the methodological ideal, following the successful development-in the 1970s-of drugs such as lovastatin (cholesterol lowering) and captopril (antihypertensive), which remain in clinical use until the present [18].In RDD, molecular modeling is used in conjunction with optimization cycles that rely on considerations of SARs to strategically modify functional chemical groups with the aim of improving the effectiveness of a drug candidate [19].</p>
<p>Curiously, this well-established method has its roots in the pioneering work of Langmuir over a century ago [20], in which the functional groups of a scaffold molecule were altered, but the essential physicochemical properties of the molecule were maintained.In medicinal chemistry, the basic principles guiding the design of such molecules-known as bioisosteres-have not changed much since Langmuir's time [21].The process of bioisosteric replacement involves finding the balance between maintaining the desired biological activity of a molecule and optimizing the drug-related properties that influence its efficacy, such as solubility, lipophilicity, stability, selectivity, non-toxicity, and absorption.In practice, bioisosteric replacement involves the use of limited and sometimes unstructured data and, as such, often relies on the intuition of a highly experienced chemist to simplify the decision-making path, say, as to the preferable sites for efficient chemical modifications on the scaffold molecule.Such intuition stems from the chemist's experience in visual chemical-structural motif recognition, and its association with retrosynthetic routes and pharmacological properties.Therefore, medicinal chemists are required to address challenges related to pattern recognition in their decision-making path toward the ultimate structure of a drug molecule.</p>
<p>Medicinal Chemistry in the Big Data Era</p>
<p>Humans have a limited capacity to process information, which forces them to use heuristics [22].In contrast, ML algorithms that depend on extensive data repositories can efficiently process vast amounts of information rapidly and accurately.This ability is beyond the capacity of any individual, no matter how expert s/he may be, to find hidden patterns.In this respect, medicinal chemists can benefit from computer-guided data analysis to inform objective and precise decisions, enabling the prediction of biologically active molecules.</p>
<p>The development of ultra-large, "make-on-demand" or "tangible" virtual libraries has significantly expanded the range of accessible drug candidate molecules.These libraries consist of compounds that have not actually been synthesized but can be readily produced.For example, the chemical suppliers Enamine [23] and OTAVA [24] offer 65 and 55 billion novel make-on-demand molecules, respectively.</p>
<p>To screen such vast chemical spaces, ultra-large-scale virtual screening for hit identification becomes essential, since direct empirical screening of billions of molecules is not feasible.Hert et al. [25] showed that for high-throughput screening of a library of the order of 10 6 molecules to succeed in returning active molecules, the library's molecules would have to be biased towards "bio-like" molecules, namely, biologically relevant compounds (such as metabolites, natural products, and drugs that mimic these substances) that proteins have evolved to recognize [26].</p>
<p>Due to the vast chemical space represented by tangible libraries, their bias toward bio-like molecules is much lower than that in "in-stock" libraries, as demonstrated in a study by Lyu et al. [26].Furthermore, that study showed that as the size of the tangible library increased, the number of better-fitting molecules also increased, with docking scores improving in a log-linear fashion with library size.Additionally, the researchers studied five ultra-large-library docking campaigns and found out that thousands of high-ranking molecules, including experimentally active compounds, such as inhibitors, were notably dissimilar to bio-like molecules.</p>
<p>In summary, the researchers obtained high-ranking unique drug candidate molecules, at the cost of vastly exhaustive and expensive computational docking testing.Nonetheless, it is important to stress that in this case, medicinal chemists would not even have suggested those high-ranking molecules as candidates for hit identification, since their dissimilarity to bio-like structures would have contradicted the heuristics commonly applied in their work.</p>
<p>While ML models offer unprecedented capacity to analyze large datasets and explore expansive chemical spaces, they are not immune to bias.In fact, when trained on historical bioactivity data, which is itself shaped by human preferences and experimental feasibility, ML algorithms can inadvertently reinforce existing biases toward well-explored, bio-like scaffolds.This can lead to the underrepresentation of structurally novel yet pharmacologically promising areas of chemical space.Moreover, many ML-driven drug discovery pipelines rely on molecular descriptors or fingerprints that are themselves biased by past datasets, creating feedback loops that marginalize atypical but viable chemical motifs.Thus, despite the theoretical reach of ultra-large virtual libraries, the effectiveness of ML in venturing into less-charted chemical regions depends heavily on the diversity and representativeness of the training data and deliberate efforts to avoid overfitting to "druglike" norms.</p>
<p>Improving the Decision-Making Process in Drug Development</p>
<p>The Ability to Predict</p>
<p>The behavioral economists Kahneman and Tversky demonstrated how humans use two paths to solve problems: One is fast and intuitive, while the other is slow and requires analytical thinking [27].In drug development, both these paths can be considerably improved by predictive models trained on datasets of molecules labeled with activity scores, providing more accurate decisions in the first path and speeding up the decision-making process in the second.To illustrate these ideas, which provide support for informed decision-making in the design of therapeutics tailored to specific biological targets, let us examine three examples.The first one is a compelling example of ML's predictive power, where Insilico Medicine used generative deep learning models to design novel inhibitors of the SARS-CoV-2 main protease (Mpro).These AI-generated lead compounds were not only chemically feasible but also synthesized and experimentally validated, demonstrating nanomolar inhibitory activity and favorable pharmacological properties [28].This end-to-end application-from target selection through molecule generation to experimental validation-highlights how predictive models can accelerate the discovery of viable therapeutic candidates tailored to complex biological targets, significantly reducing development timelines.</p>
<p>The second example centers on quantitative structure-activity relationships (QSARs) analysis, a computer-aided method used in the hit-to-lead process.This methodology (based on the seminal publication of Hansch et al. that appeared in 1962 [29]) is utilized to predict differences in the biological activities of chemical compounds by correlating them with a quantitative description of variations in their structures [30].By leveraging deep learning methods, which have been employed to develop advanced QSAR models (designated as "deep QSAR models"), quantum mechanics calculations can now be performed more efficiently, reducing computational time and improving the accuracy of the relevant QSAR models [31].This enhancement, in turn, contributes to higher accuracy in calculating ligand binding affinity and molecular properties and ultimately improves the ability to identify promising drug candidates [31].For example, Rufa et al. [32] used a hybrid approach combining ML with molecular mechanics to achieve a root mean square error (RMSE) of 0.47 kcal/mol for binding free energy predictions-nearly halving the error (originally 0.97 kcal/mol) of conventional molecular mechanics alone.Deep QSAR models have recently been combined with chemical language models, either as separate external tools to rank the generated molecules by activity or as model-intrinsic scoring functions to guide chemical structure generation towards molecules with particular properties [33][34][35].We take the third example from the ADMET analysis step of drug discovery, where physicochemical properties critical to pharmacokinetics and formulation are optimized.One such property is the octanol−water partition coefficient (log P)-a key measure of lipophilicity.It indicates how a compound distributes between aqueous and lipid environments, thereby influencing its behavior in biological systems.A drug with a high log p value typically exhibits enhanced membrane permeability due to favorable partitioning into lipid bilayers, but this may also lead to reduced aqueous solubility and suboptimal bioavailability.Conversely, compounds with low log p values may struggle to cross lipid membranes, limiting absorption.The log p value of a compound also correlates with other drug-relevant properties, such as excretion, metabolic stability, and tissue distribution [36].Since it may be difficult to determine log P experimentally for particular compounds and for some ranges of log P, quantum-mechanics-based tools have emerged as a preferred alternative to existing empirical models [37].However, they demand a substantial computational cost of around 1 h per compound [37].To address this problem, Lewis et al. [37] trained a message-passing neural network model, known as Chemprop, on both a public dataset of compounds and a Novartis in-house dataset, to obtain a computationally affordable quantum-mechanics-based predictive model of drug lipophilicity values for hundreds of compounds per second.Their Chemprop-based model achieved mean absolute errors (MAEs) of 0.44 and 0.34 log units on scaffold-split test sets of public and in-house datasets, outperforming traditional regression models and demonstrating scalability and predictive robustness.In addition, using learning curves, they showed that additional training data for both the public and in-house datasets could probably further decrease the test set error.It would thus seem that their model could be used to pre-screen large libraries of compounds, making it useful in the decision-making process of prioritization of candidate compounds for full quantum mechanics calculations of the likelihood that a particular compound would succeed in clinical studies.</p>
<p>Man vs. Machine</p>
<p>Humans have the creative ability to develop new hypotheses and ideas that are not based on prior information or observations [38].In the human decision-making process, this ability is enhanced by integrating considerations beyond the capacity of algorithms, for example, ethical rules, non-specific drug effects, and even long-term strategies in drug development.Figure 2 presents a graphical comparison of this human capability with that of ML in terms of the relative difficulty of performing different tasks related to drug design and medicinal chemistry.Each task-for human vs. computer-aided capabilities-is represented by a circle, whose size indicates the complexity of the calculation involved vs. the complexity of the algorithm (the larger the circle, the more complex the task) and whose shade of color represents the level of expertise required vs. the size of dataset needed for the ML algorithm to perform effectively.For instance, the shade of the blue circle representing the "conclusions drawn from SARs" indicates that medium-sized datasets can be utilized (intermediate shade of blue) and that the conclusions can be drawn by simple linear ML algorithm (enclosed within the dashed circle) or more complex ones (non-linear algorithms to neural networks) [39].In contrast, the large dark blue circles for the "design of chemical synthesis" or "synthetic creativity", i.e., generating new molecules, require complex ML algorithms and large datasets [40,41].</p>
<p>the complexity of the algorithm (the larger the circle, the more complex the task) and whose shade of color represents the level of expertise required vs. the size of dataset needed for the ML algorithm to perform effectively.For instance, the shade of the blue circle representing the "conclusions drawn from SARs" indicates that medium-sized datasets can be utilized (intermediate shade of blue) and that the conclusions can be drawn by simple linear ML algorithm (enclosed within the dashed circle) or more complex ones (non-linear algorithms to neural networks) [39].In contrast, the large dark blue circles for the "design of chemical synthesis" or "synthetic creativity", i.e., generating new molecules, require complex ML algorithms and large datasets [40,41].Darker green means that higher expertise is required to accomplish the task.Lighter green means that lower expertise or a more novice level will accomplish the task.</p>
<p>As is apparent from the above discussion, humans have a clear advantage in solving complex problems that require a holistic overview of systems or adaptations to changing, unpredictable, or unfamiliar situations, such as changes that must be made to comply with Lighter blue means that smaller datasets can be used.Green represents the level of human expertise needed.Darker green means that higher expertise is required to accomplish the task.Lighter green means that lower expertise or a more novice level will accomplish the task.</p>
<p>As is apparent from the above discussion, humans have a clear advantage in solving complex problems that require a holistic overview of systems or adaptations to changing, unpredictable, or unfamiliar situations, such as changes that must be made to comply with updated regulations for particular drugs.In contrast, the advantage of ML algorithms lies in the ease with which they can identify patterns in high-dimensional chemical data, even if the patterns are weak and hidden in a large dataset [42].The medicinal chemist can, therefore, leverage ML as a complementary tool to effectively utilize big data to reveal patterns and hidden features and, hence, to establish rules to build generalized, fast, and accurate models.It should, nonetheless, be remembered that while ML provides valuable insights and information, it cannot completely replace the expertise, creativity, and intuition of the medicinal chemist.Even validated ML models often overlook the specific context of the drug discovery project and do not take into account the downstream assays that are crucial for experimentally validating the model's predictions.For example, if a model predicts toxicity, it is essential to understand what this prediction means in terms of the type of disease (e.g., lifestyle-related illness or terminal cancer), dosage, target tissue, etc.</p>
<p>In this context, the experience and intuition of a medicinal chemist will play a crucial part in assessing a model's predictions.These ideas are reflected in Table 1, which summarizes the capabilities and limitations of ML and human expertise in drug discovery tasks.Furthermore, as AI systems play an increasing role in molecule design, their integration into the drug development pipeline must be accompanied by a careful examination of both ethical and regulatory frameworks.Current regulatory bodies, such as the FDA and EMA, are beginning to adapt their guidelines to assess AI-generated outputs, but there remains uncertainty regarding the validation, transparency, and accountability of models that operate as "black boxes" [43].Without explainability, it becomes difficult to justify how and why certain molecules were selected for further development, posing a challenge to regulatory approval.Ethically, there are concerns about delegating creative and high-stakes decisions to machines, especially in areas where unintended consequences, such as off-target effects or biases in training data, could have significant impacts on patient safety [44].Additionally, the rapid pace of AI innovation can outstrip the ability of governance structures to evaluate risks and ensure equity, such as fair access to AI-accelerated therapies.This highlights the need for explainable AI (XAI) mechanisms, which help improve transparency and ensure that AI decisions are understood, reducing risks related to algorithmic biases and increasing trust in AI systems used in drug discovery [43,44].Ultimately, while AI can serve as a powerful complement to human expertise, it also necessitates a collaborative approach in which the human expert remains the final arbiter of judgment, balancing machine-generated suggestions with ethical responsibility, contextual knowledge, and regulatory foresight.</p>
<p>Machine Decision Making</p>
<p>Chemical and Visual Descriptors</p>
<p>As mentioned above, ML algorithms can easily identify patterns in molecular structures that would improve the function of particular drug molecules [42].An essential aspect of analyzing these patterns begins with a molecular representation of the chemical data [45].One of the "tools" that has been applied for this purpose is graph theory, but the representation of molecules by graphs composed of vertices (atoms) and connecting edges (bonds) is sparse due to the limited connectivity between the atoms in the molecules.Additional drawbacks of graph-based representations are that they lack uniqueness (since different connectivity tables can represent the same chemical structure) and they are not adequate for representing certain types of molecules, particularly aromatic and organometallic compounds [46].</p>
<p>In seeking a more satisfactory means for molecular representation of chemical data, Akabayov and his colleagues recently explored various feature extraction methods to train supervised models that predict the binding of small molecules to RNA targets [47,48].To extract chemical descriptors and geometrical patterns that aid in the understanding-and prediction-of molecule-RNA binding affinities, those studies analyzed various molecular representations (including SMILES strings-simplified molecular input line entry system and pictorial representations) by employing Lasso regression, decision tree classifiers, and convolutional neural network (CNN) models.While CNNs applied to molecular images can uncover complex spatial and visual features, their outputs are often considered less chemically interpretable compared to graph-based or descriptor-driven methods [49].To address this, the mentioned study [47] has integrated CNN-derived visual features with chemically defined descriptors, such as solubility, molecular regularity, and counts of hydroxy and amino groups, thereby anchoring model predictions in chemically meaningful patterns.Since then, emerging model interpretability techniques, such as saliency mapping and feature attribution methods, can help identify which image regions drive predictions [50,51], improving the chemical relevance of CNN-based insights.These integrative approaches exemplify the evolving notion of the informacophore, which extends traditional pharmacophore modeling by combining human-interpretable chemical features with data-driven, ML representations to enhance understanding of molecular recognition across diverse biological targets.Collectively, these studies facilitate a unique understanding of the interplay between molecular structure and biological activity, and, in the case of small molecules binding to RNA targets, the identification of intrinsic properties of potent inhibitors.</p>
<p>Reducing the Complexity of a Molecule</p>
<p>Efficient exploration of the vast, novel chemical landscapes enhances the prospects for early-stage discovery of effective drug candidates [52].However, the chemical search space for pharmacologically relevant small molecules is enormous [53]-being of the order of 10 60 .This sheer size makes it extremely challenging to efficiently identify candidate compounds with the desired bioactivity from the full search space.This inefficiency is due to the very limited chemical space covered by small molecule libraries [54,55], which results in a low hit rate in high-throughput screening (HTS) of libraries of the order multimillions of compounds.</p>
<p>A powerful approach to aid in easing this problem is fragment-based drug discovery (FBDD), which offers several advantages over HTS campaigns [56].FBDD leverages the concept that small chemical fragments (with low molecular weights of less than 300 Da) that bind weakly to specific sites on a target protein can be elaborated into larger more complex molecules that can serve as potent lead candidates [57].The premise underlying FBDD is that in HTS studies higher hit rates will be obtained for such small fragment molecules than for full drug-like molecules possessing functional groups that may pose steric hindrance or electrostatic repulsion in a binding site [58,59].Thus, FBDD facilitates the exploration of a broader chemical space with fewer fragment compounds.However, it is also important to notice that fragments often exhibit very weak binding affinities, making them difficult to detect without sensitive biophysical methods such as X-ray crystallography, NMR spectroscopy, and isothermal titration calorimetry (ITC) [60].Additionally, many fragment hits face solubility issues, and their synthetic elaboration into drug-like molecules can be non-trivial.These challenges can hinder the optimization process from fragment to lead compound [61].</p>
<p>A practicable strategy to reduce the vast chemical search space for drug-sized (small) molecules with enhanced bio-activity is the use of the same scaffold as that obtained by fragment-based screening [62].In applying this strategy, the Akabayov group first used NMR transverse relaxation times (T2 relaxation) as a fragment screening method to identify a hit functional chemical group that binds to an RNA target [48,63].The group then followed a hit-to-lead workflow that included a two-step computational optimization [63] with the aim of increasing the size of the molecule and, at the same time, extending the network of weak interactions between the small molecule and the RNA target.This approach enhanced both the specificity and strength of small molecule-RNA binding, moving the compound closer to a viable lead.By starting from a validated fragment scaffold, it was possible to efficiently navigate the chemical space to design drug-sized molecules with improved bioactivity.</p>
<p>The Informacophore and Inverse Cheminformatics</p>
<p>In computationally aided drug discovery, data-driven algorithms are used to reveal the features critical for the activity of a small molecule in binding to a biological target, such as a protein or receptor [64].These key features, which comprise the chemical and structural fingerprints of a small molecule, form the informacophore, which represents the minimal chemical structure required to induce biological activity.Conceptually, the informacophore can be viewed as a refined, function-oriented scaffold-a minimal framework that retains only the essential elements for target binding.</p>
<p>The informacophore is often slightly larger than a molecular fragment, yet it contains only those atoms or functional groups necessary for molecular recognition, acting much like a "key" that fits a specific "lock".For instance, if a compound is found to bind strongly to a particular protein, the informacophore of that compound consists of the minimal set of atoms or functional groups responsible for this interaction.By analyzing a collection of molecules with shared informacophore features, researchers can cluster compounds with similar biological activity profiles and predict the activity of new molecules based on their informacophore structure.This approach dramatically narrows the chemical search space, enabling more efficient virtual screening and compound optimization.Cheminformatics tools, which extract molecular descriptors from chemical structures, play a crucial role in identifying informacophores and predicting bioactivity.By analyzing the informacophore of a molecule, through the extraction of structural descriptors and visual patterns from chemical data, researchers can model and anticipate its biological activity.For example, the informacophore of Imatinib, an established cancer drug, can be computationally derived and used to predict the activity of other compounds that share similar informacophorederived features and are likely to exhibit comparable binding profiles to the same target.</p>
<p>Conversely, in the reverse process, known as inverse cheminformatics, novel bioactive molecules may be created by applying design principles based on extracted chemical patterns [65].This reverse process allows scientists to design new compounds systematically, guided by a detailed understanding of the chemical properties and biological interactions derived from cheminformatics, ultimately leading to the development of effective and targeted therapeutic agents [66].Figure 3 compares the direct and inverse design paradigms, illustrating the chemical and functional space transition.In the direct design approach, one starts from chemical structures and evaluates their corresponding properties.Conversely, inverse design begins with desired functional properties and searches for chemical structures that meet those criteria.The figure was redrawn based on ref. [65].For inverse design, two main pathways are commonly employed: (i) Virtual screening of functional space to identify optimal combinations of molecular properties-often through large databases or predictive models.For example, in a recent study, Menacer et al. [67] introduced a novel methodology integrating inverse-QSAR with molecular dock-ing for the de novo design of SARS-CoV-2 main protease inhibitors.By utilizing simple, reversible descriptors, their approach addressed the limitations of traditional inverse-QSAR techniques and enabled the generation of novel scaffold-based structures with predicted activity.This approach balances predictive accuracy with interpretability by ensuring that the descriptors used in the inverse-QSAR model retain chemical meaning.(ii) Optimization through the traversal of functional space using generative models, such as variational autoencoders (VAEs), generative adversarial networks (GANs), and conditional recurrent neural networks (cRNNs).Table 2 summarizes the key characteristics of these generative model architectures explored in recent molecular design efforts.Each model type offers unique advantages in how molecules are represented, generated, and optimized.</p>
<p>The complexity of such generative models raises concerns about their lack of direct interpretability [66].These models may generate highly complex molecular structures, but understanding the underlying decision-making process remains a significant challenge.Researchers are beginning to address this by developing hybrid approaches that combine deep learning with traditional cheminformatics to ensure the generated molecules are not only novel but also chemically plausible [68,69].However, despite their promise, generative approaches face significant challenges in translating in silico designs into viable drug candidates.A major limitation lies in the failure rate of generated molecules-many may be chemically unstable, synthetically inaccessible, or biologically irrelevant [70].For instance, molecules sampled from latent spaces can satisfy mathematical constraints but fail to meet key medicinal chemistry criteria, such as Lipinski's rules, toxicity thresholds, or reactivity filters.Furthermore, synthetic feasibility is a critical bottleneck: a molecule's theoretical desirability is insufficient unless it can be practically synthesized [71].Recent efforts have introduced retrosynthesis-aware filters and synthetic accessibility scoring (SAS) functions into generative workflows, but these tools remain imperfect [72].</p>
<p>Additional post-generation filtering is often required to assess drug-likeness and eliminate structures that, while novel, may fall outside the boundaries of known pharmacophores.For instance, models such as MolFilterGAN have shown promise in triaging AI-designed molecules by integrating synthetic feasibility and biological relevance [73].Furthermore, retrosynthesis-aware scoring tools like RAscore have made it possible to incorporate synthesizability directly into generative processes, helping bridge the gap between theoretical generation and practical chemistry [72].These developments underscore the necessity for inverse design pipelines to integrate comprehensive evaluation steps that prioritize candidates not only for novelty and predicted activity, but also for synthesizability, pharmacological relevance, and safety.</p>
<p>An emerging and highly complementary strategy to enhance the performance of these generative models-especially in scenarios with limited labeled data-is transfer learning.Transfer learning enables models trained on large, general-purpose chemical datasets to be fine-tuned for more specific, data-scarce applications such as RNA-targeted ligand prediction.This approach has shown that even complex property prediction tasks can benefit from knowledge learned in adjacent domains, especially when leveraging shared latent representations.For instance, recent studies have demonstrated that transfer learning using latent variables, such as those derived from autoencoders, can significantly improve property prediction in low-data regimes without sacrificing performance in high-data settings [74].Importantly, this strategy is not limited to VAEs.GANs can incorporate transfer learning by initializing the generator and discriminator with weights pretrained on large molecular datasets, enhancing their ability to generate chemically valid structures from limited task-specific data.Similarly, cRNNs can be pretrained on large corpora of SMILES strings and later conditioned on task-relevant features for fine-tuned generation of molecules that meet specific property constraints.By embedding transfer learning within these generative frameworks, researchers can build models that not only generalize better across diverse chemical tasks but also accelerate discovery in niche domains where experimental data is inherently limited [74].</p>
<p>Outlook</p>
<p>The application of ML and cheminformatics in drug design is advancing rapidly, due both to significant improvements in data collection, storage capacity, and computational power and to the availability of specialized ML algorithms.This progress has enabled the identification of key molecular features that enhance the accuracy of predictive models.The current shift towards more efficient and informed drug design processes may thus be regarded as the synergetic combination of computational models and the expertise of medicinal chemists.</p>
<p>However, as AI-driven methods become more integrated into drug discovery, it is essential to acknowledge their limitations.These include challenges such as model explainability [80], data bias, and the risk of underfitting or overfitting [81].AI models are only as good as the data they are trained on, and biases in data can lead to inaccurate or skewed predictions [82].Additionally, the lack of transparency in some ML models can hinder the ability to interpret how decisions are made, raising concerns about trust and accountability in drug development [80].Therefore, despite their immense potential, AI and ML tools must be used with caution and always in conjunction with human oversight.Ongoing validation-especially through laboratory experiments-and careful monitoring are crucial to ensure that these technologies lead to meaningful and safe therapeutic advancements.As computational technologies continue to evolve, their effective integration with expert human judgment will be essential, creating a synergistic dynamic that not only accelerates drug discovery but also enhances the reliability and precision of therapeutic interventions.</p>
<p>To conclude, AI and ML are not here to replace human ingenuity in medicinal chemistry, but to augment it.The future of drug discovery lies in a collaborative approach, where computational models and human expertise work together to push the boundaries of what is possible.Advanced AI techniques will enhance the capabilities of medicinal chemists, allowing them to make more informed, precise, and innovative decisions.The path forward is one where AI and human insight converge to revolutionize the field, making drug discovery faster, more accurate, and ultimately more impactful.Looking ahead, we propose two possible key evolution routes that will drive the future of drug discovery:</p>
<p>• The first involves FBDD and make-on-demand compound libraries, which will enable virtual searches for bioactive compounds rather than relying on traditional HTS.This shift will streamline the drug discovery process, reducing the need for extensive physical screening, as was the case in the past 25 years [83].</p>
<p>• The second route focuses on advancements in molecular representations.As tradi- tional representations like SMILES and graph-based representations fail to capture the complexity of large molecules [84], there is a need for more sophisticated representations that improve the accuracy of property predictions and virtual screening.These developments will enhance the performance of ML algorithms and help produce more reliable and precise drug discovery outcomes.</p>
<p>Together these routes will work in tandem to improve the power and reliability of ML algorithms in drug discovery.Furthermore, an understanding of how molecular representations influence model interpretability [85] could provide valuable insights for medicinal chemists, allowing them to leverage AI-driven decisions to inform their own expertise and judgment.As the integration of AI into drug discovery continues to evolve, these advancements will ensure that human oversight remains central, with AI serving as a powerful tool for enhancing, rather than replacing, human intuition and expertise.</p>
<p>Figure 1 .
1
Figure 1.Overview of different steps in the drug discovery pipeline and the corresponding computational tools that may be applied to expedite each step.ADMET-absorption, distribution, metabolism, excretion, and toxicity; QSAR-quantitative structure-activity relationships; NLP-natural language processing.</p>
<p>Figure 1 .
1
Figure 1.Overview of different steps in the drug discovery pipeline and the corresponding computational tools that may be applied to expedite each step.ADMET-absorption, distribution, metabolism, excretion, and toxicity; QSAR-quantitative structure-activity relationships; NLP-natural language processing.</p>
<p>Figure 2 .
2
Figure 2. The complexity of drug design and medicinal chemistry tasks (depicted by circles) for machine learning (ML) algorithms vs. human capabilities.The meanings of the circle sizes are as follows: Larger circles represent more complex ML algorithms or require higher human expertise.Smaller circles represent simpler ML algorithms or require less human expertise.The meanings of the circle shade colors are as follows: Blue represents the size of the dataset needed for training ML algorithms.Darker blue means that larger datasets are required for better decision-making.Lighter blue means that smaller datasets can be used.Green represents the level of human expertise needed.</p>
<p>Figure 2 .
2
Figure 2. The complexity of drug design and medicinal chemistry tasks (depicted by circles) for machine learning (ML) algorithms vs. human capabilities.The meanings of the circle sizes are as follows: Larger circles represent more complex ML algorithms or require higher human expertise.Smaller circles represent simpler ML algorithms or require less human expertise.The meanings of the circle shade colors are as follows: Blue represents the size of the dataset needed for training ML algorithms.Darker blue means that larger datasets are required for better decision-making.Lighter blue means that smaller datasets can be used.Green represents the level of human expertise needed.Darker green means that higher expertise is required to accomplish the task.Lighter green means that lower expertise or a more novice level will accomplish the task.</p>
<p>Pharmaceutics 2025, 17, x FOR PEER REVIEW 13 of 18</p>
<p>Figure 3 .
3
Figure 3. Schematic representation of the different approaches to molecular design.The direct approach (top) leads from chemical space to the properties of the molecule, whereas inverse design (bottom) proceeds from the desired properties to chemical space.Left: a 2D projection of a highdimensional property landscape illustrates functional space; right: example molecular structures.</p>
<p>Figure 3 .
3
Figure 3. Schematic representation of the different approaches to molecular design.The direct approach (top) leads from chemical space to the properties of the molecule, whereas inverse design (bottom) proceeds from the desired properties to chemical space.Left: a 2D projection of a highdimensional property landscape illustrates functional space; right: example molecular structures.The figure was redrawn based on ref. [65].</p>
<p>Table 1 .
1
Comparison of ML vs. human expertise in drug discovery tasks.This table highlights the strengths and limitations of both ML models and human expertise across key tasks in drug discovery, including molecule design, SAR analysis, toxicity prediction, chemical synthesis planning, biological target identification, and clinical trial design.
TaskML CapabilitiesML LimitationsHuman Expertise CapabilitiesHuman Expertise LimitationsMolecule Design/Synthetic CreativityRapidly generates novel molecular structures from extensive datasets. Efficient in exploring vast chemical spaces. Identifies subtle, non-obvious molecular features.Struggles with understanding context-specific details, such as disease nuances. Lacks insight into biological or off-target effects. May not propose innovative designs beyond existing data.Can generate truly novel ideas and hypotheses. Integrates biological, therapeutic, and regulatory contexts. Has intuition for unexpected solutions.Time-consuming. Limited by experience in specific areas. Limited ability of using large datasets for pattern recognition.SAR analysisAnalyzes high-dimensional datasets to identify pattern. Quickly generates predictive models to assess activity across compounds.Models can fail with noisy data. The models may struggle with complex relationships between molecular features. data quality. Performance relies on trainingExpertise in interpreting contextual nuances of SAR data. Flexible in assessing novel biological effects. relationships or unexpectedLimited ability to analyze large datasets manually. Biases may influence interpretation.Missing rare orInsights may be generatedcontext-specific toxicity risks.Contextual understanding ofslowly, slowing downCapable of analyzingLacking biological insight intoxicity, such as tissue typedecision-making.Toxicityextensive datasets of toxicitycertain cases.and dosage.May lead to missingPredictionreports to forecast potentialBeing unable to considerAbility to interpret complex,emerging trends or newtoxicological effects.contextual factors such asmultifactorial interactionspatterns and hinderpatient-specific variables likethat lead to toxicity.innovationage and comorbidities.and adaptability.Chemical Synthesis PlanningCan predict viable synthetic routes using comprehensive datasets from prior reactions. Identifies efficient reaction conditions and reagents.Being constrained by existing data, which may prevent the generation of truly novel synthesis pathways. Struggles with complex, multi-step synthesis that requires intuition or innovative thinking.The ability to improvise when synthetic routes are ineffective. An intuitive understanding of how to adapt synthesis methods based on specific compound structures.Struggles with scalability for a large number of compounds. Resource constraints in synthetic efforts can limit creativity.Biological Target IdentificationCan analyze extensive genomic and proteomic datasets to identify potential drug targets. Employs a data-driven and systematic approach to candidate targets. searching forLack of contextual understanding of disease biology and patient variability. May overlook rare or novel biological targets that are not training data. represented in theDeep understanding of biological mechanisms in specific diseases. Ability to contextualize target discovery through and experience. biological insightOften struggle with large-scale data integration. Slower to recognize new or unexpected targets.Clinical Trial DesignCan optimize trial designs by analyzing data of a certain statistical distribution and identifying factors influencing patient outcomes.Challenge in integrating individual patient differences or ethical considerations. Lacks the ability to generate human-centered solutions based on societal needs.Ability to design trials with a focus on human factors, ethics, and patient variability. Adapts trial design to real-world conditions. emerging data andTime-consuming and resource-intensive. Can be inflexible when adapting existing designs to new conditions.</p>
<p>Table 2 .
2
Overview of generative model architectures commonly used in molecular design.Each model type is characterized by its core purpose in handling chemical representations, a defining feature that underlies its generative capability, and representative studies that have contributed to its development and application in drug discovery or molecular optimization.
Model TypeChemical PurposeKey FeatureReferenced StudiesVAE (Variational Autoen-coder)Encode molecules into a con-tinuous latent space and de-code to generate novel chemi-Smooth latent space allows inter-polation and optimization of mo-Gómez-Bombarelli et al. [75]</p>
<p>Table 2 .
2
Overview of generative model architectures commonly used in molecular design.Each model type is characterized by its core purpose in handling chemical representations, a defining feature that underlies its generative capability, and representative studies that have contributed to its development and application in drug discovery or molecular optimization.The study by Insilico Medicine's, discussed earlier in Section 2.1, is marked with an asterisk.
Model TypeChemical PurposeKey FeatureReferenced StudiesEncode molecules into aVAE (Variational Autoencoder)continuous latent space and chemically decode to generate novelSmooth latent space allows of molecular properties interpolation and optimizationGómez-Bombarelli et al. [75]meaningful structuresLearn to generate validAdversarial training enablesGAN (Generativemolecular structures by traininggeneration of novel moleculesZhavoronkov et al. * [28]Adversarial Network)a generator against awith predefinedKadurin et al. [76]discriminatorbioactivity profilescRNN (Conditional Recurrent Neural Network)Learn physicochemical or structural characteristics to generate molecules conditioned on desired propertiesSequential generation of molecules guided by learned property constraintsKotsias et al. [77] Mohapatra et al. [78]Model the exact likelihood ofEnables bidirectional mappingFlow-based Neural Networkmolecular data forbetween molecule and latentHu Wei [79]reversible generationspace with tractable likelihoods
*</p>
<p>Funding: This research was supported by the Ministry of Defense (Grant No. 4441137465) and the Ministry of Innovation, Science and Technology (Grant No. 0005983).Conflicts of Interest:The authors declare no conflict of interest.
Drug discovery: An appraisal. V Umashankar, S Gurunathan, Int. J. Pharm. Pharm. Sci. 72015</p>
<p>Advancing drug discovery via artificial intelligence. H S Chan, H Shan, T Dahoun, H Vogel, S Yuan, 10.1016/j.tips.2019.06.004Trends Pharmacol. Sci. 402019</p>
<p>Revolutionizing Drug Discovery: A Comprehensive Review of AI Applications. R Dhudum, A Ganeshpurkar, A Pawar, 10.3390/ddc3010009Drugs Drug Candidates. 2024</p>
<p>An artificial intelligence accelerated virtual screening platform for drug discovery. G Zhou, D V Rusnac, H Park, D Canzani, H M Nguyen, L Stewart, M F Bush, P T Nguyen, H Wulff, V Yarov-Yarovoy, 10.1038/s41467-024-52061-7Nat. Commun. 1577612024</p>
<p>Target validation using chemical probes. M E Bunnage, E L Chekler, L H Jones, 10.1038/nchembio.1197Nat. Chem. Biol. 92013</p>
<p>Opportunities and challenges in phenotypic drug discovery: An industry perspective. J G Moffat, F Vincent, J A Lee, J Eder, M Prunotto, 10.1038/nrd.2017.111Nat. Rev. Drug Discov. 162017</p>
<p>Artificial intelligence in drug development: Present status and future prospects. K K Mak, M R Pichika, 10.1016/j.drudis.2018.11.014Drug Discov. Today. 242019</p>
<p>How were new medicines discovered?. D C Swinney, J Anthony, 10.1038/nrd3480Nat. Rev. Drug Discov. 102011</p>
<p>Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. P Richardson, I Griffin, C Tucker, D Smith, O Oechsle, A Phelan, M Rawling, E Savory, J Stebbing, 10.1016/S0140-6736(20)30304-4Lancet. 3952020</p>
<p>Bloom-Ackermann, Z. A deep learning approach to antibiotic discovery. J M Stokes, K Yang, K Swanson, W Jin, A Cubillos-Ruiz, N M Donghia, C R Macnair, S French, L A Carfrae, 10.1016/j.cell.2020.01.021Cell. 1802020e613. [CrossRef</p>
<p>A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. D E Gordon, G M Jang, M Bouhaddou, J Xu, K Obernier, K M White, M J O'meara, V V Rezelj, J Z Guo, D L Swaney, 10.1038/s41586-020-2286-9Nature. 5832020</p>
<p>Multiscale interactome analysis coupled with off-target drug predictions reveals drug repurposing candidates for human coronavirus disease. M G Sugiyama, H Cui, D S Redka, M Karimzadeh, E Rujas, H Maan, S Hayat, K Cheung, R Misra, J B Mcphee, 10.1038/s41598-021-02432-7Sci. Rep. 2021, 11, 23315</p>
<p>Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. G Bollag, P Hirth, J Tsai, J Zhang, P N Ibrahim, H Cho, W Spevak, C Zhang, Y Zhang, G Habets, 10.1038/nature09454Nature. 4672010</p>
<p>Meaningful machine learning models and machinelearned pharmacophores from fragment screening campaigns. C Poelking, G Chessari, C W Murray, R J Hall, L Colwell, M Verdonk, 10.48550/arXiv.2204.06348arXiv:2204.063482022</p>
<p>Explainable machine learning for property predictions in compound optimization: Miniperspective. R Rodríguez-Pérez, J Bajorath, 10.1021/acs.jmedchem.1c01789J. Med. Chem. 642021</p>
<p>Structure-Based Drug Discovery Paradigm. M Batool, B Ahmad, S Choi, 10.3390/ijms20112783Int. J. Mol. Sci. 2019, 20, 2783</p>
<p>Integrating research and development: The emergence of rational drug design in the pharmaceutical industry. M Adam, 10.1016/j.shpsc.2005.07.003Stud. Hist. Philos. Biol. Biomed. Sci. 362005</p>
<p>Science and innovation: The US pharmaceutical industry during the. A Gambardella, 1980s. 1995Cambridge University PressCambridge, UK</p>
<p>Structure-activity relationships for the design of small-molecule inhibitors. A D Andricopulo, C A Montanari, 10.2174/1389557054023224Mini Rev. Med. Chem. 52005</p>
<p>. I Langmuir, Isosterism Isomorphism, Covalence , 10.1021/ja02231a009J. Am. Chem. Soc. 411919</p>
<p>The Design and Application of Bioisosteres in Drug Design. N A Meanwell, Burger's Med. Chem. Drug Discov. 2021</p>
<p>Human problem solving: The state of the theory in 1970. H A Simon, A Newell, 10.1037/h0030806Am. Psychol. 261451971</p>
<p>. Enamine, 25 April 2025</p>
<p>. Chemriya, 25 April 2025</p>
<p>Quantifying biogenic bias in screening libraries. J Hert, J J Irwin, C Laggner, M J Keiser, B K Shoichet, 10.1038/nchembio.180Nat. Chem. Biol. 52009</p>
<p>Modeling the expansion of virtual screening libraries. J Lyu, J J Irwin, B K Shoichet, Nat. Chem. Biol. 192023</p>
<p>Prospect theory: An analysis of decision under risk. D Kahneman, A Tversky, Handbook of the Fundamentals of Financial Decision Making: Part I; World Scientific. Singapore2013</p>
<p>Potential 2019-nCoV 3C-like protease inhibitors designed using generative deep learning approaches. A Zhavoronkov, V Aladinskiy, A Zhebrak, B Zagribelnyy, V Terentiev, D S Bezrukov, D Polykovskiy, R Shayakhmetov, A Filimonov, P Orekhov, 10.26434/chemrxiv.11829102.v2Preprint v2 from ChemRxiv 2020. [CrossRef</p>
<p>Correlation of biological activity of phenoxyacetic acids with Hammett substituent constants and partition coefficients. C Hansch, P P Maloney, T Fujita, R M Muir, 10.1038/194178b0Nature. 1941962</p>
<p>3D-QSAR in drug design--a review. J Verma, V M Khedkar, E C Coutinho, 10.2174/156802610790232260Curr. Top. Med. Chem. 102010</p>
<p>Integrating QSAR modelling and deep learning in drug discovery: The emergence of deep QSAR. A Tropsha, O Isayev, A Varnek, G Schneider, A Cherkasov, 10.1038/s41573-023-00832-0Nat. Rev. Drug Discov. 232024</p>
<p>Towards chemical accuracy for alchemical free energy calculations with hybrid physics-based machine learning/molecular mechanics potentials. D A Rufa, H E Bruce Macdonald, J Fass, M Wieder, P B Grinaway, A E Roitberg, O Isayev, J D Chodera, 10.1101/2020.07.29.2279592020Preprint from BioRxiv</p>
<p>Chemical language models for de novo drug design: Challenges and opportunities. F Grisoni, 10.1016/j.sbi.2023.102527Curr. Opin. Struct. Biol. 792023. 102527</p>
<p>Generative and reinforcement learning approaches for the automated de novo design of bioactive compounds. M Korshunova, N Huang, S Capuzzi, D S Radchenko, O Savych, Y S Moroz, C I Wells, T M Willson, A Tropsha, O Isayev, 10.1038/s42004-022-00733-0Commun. Chem. 2022, 5, 129. [CrossRef</p>
<p>De Novo Molecular Design with Chemical Language Models. F Grisoni, G Schneider, Methods Mol. Biol. 23902022</p>
<p>Lipophilicity in drug design: An overview of lipophilicity descriptors in 3D-QSAR studies. T Ginex, J Vazquez, E Gilbert, E Herrero, F J Luque, 10.4155/fmc-2018-0435Future. Med. Chem. 112019</p>
<p>Machine intelligence models for fast, quantum mechanics-based approximation of drug lipophilicity. R Lewis, C Isert, J Kromann, N Stiefl, G Schneider, 10.1021/acsomega.2c05607ACS Omega. 82023</p>
<p>Imagination and the generation of new ideas. R W Magid, M Sheskin, L E Schulz, 10.1016/j.cogdev.2014.12.008Cogn. Dev. 342015</p>
<p>Do we need different machine learning algorithms for QSAR modeling? A comprehensive assessment of 16 machine learning algorithms on 14 QSAR data sets. Z Wu, M Zhu, Y Kang, E L Leung, T Lei, C Shen, D Jiang, Z Wang, D Cao, T Hou, 10.1093/bib/bbaa321Brief. Bioinform. 222021bbaa321. [CrossRef</p>
<p>Machine Learning in Computer-Aided Synthesis Planning. C W Coley, W H Green, K F Jensen, 10.1021/acs.accounts.8b00087Acc. Chem. Res. 512018</p>
<p>On Characterizations of Large Language Models and Creativity Evaluation. M Peeperkorn, D Brown, A Jordanous, 2023UKUniversity of Kent: Canterbury</p>
<p>Integrating Artificial Intelligence for Drug Discovery in the Context of Revolutionizing Drug Delivery. A I Visan, I Negut, 10.3390/life14020233Life. 142332024</p>
<p>Explainability and white box in drug discovery. K K Kirboga, S Abbasi, E U Kucuksille, 10.1111/cbdd.14262Chem. Biol. Drug Des. 1022023</p>
<p>Ethical Considerations Emerge from Artificial Intelligence (AI) in Biotechnology. M Dara, N Azarpira, 10.18502/ajmb.v17i1.17680Avicenna J. Med. Biotechnol. 172025</p>
<p>Molecular representations for machine learning applications in chemistry. S Raghunathan, U D Priyakumar, 10.1002/qua.26870Int. J. Quantum Chem. 1222022. e26870</p>
<p>Molecular representations in bio-cheminformatics. T H Nguyen-Vo, P Teesdale-Spittle, J E Harvey, B P Nguyen, 10.1007/s12293-024-00414-6Memet. Comput. 162024</p>
<p>Machine learning approaches to optimize small-molecule inhibitors for RNA targeting. H Grimberg, V S Tiwari, B Tam, L Gur-Arie, D Gingold, L Polachek, B Akabayov, 10.1186/s13321-022-00583-xJ. Cheminform. 142022</p>
<p>Discovery of small-molecule inhibitors targeting the ribosomal peptidyl transferase center (PTC) of M. tuberculosis. B Tam, D Sherf, S Cohen, S A Eisdorfer, M Perez, A Soffer, D Vilenchik, S R Akabayov, G Wagner, B Akabayov, 10.1039/C9SC02520KChem. Sci. 102019</p>
<p>Visual interpretability for deep learning: A survey. Q S Zhang, S C Zhu, Front. Inf. Technol. Electron. Eng. 192018</p>
<p>Gradient based feature attribution in explainable ai: A technical review. Y Wang, T Zhang, X Guo, Z Shen, 10.48550/arXiv.2403.10415arXiv:2403.104152024</p>
<p>The (Un)reliability of Saliency Methods. P.-J Kindermans, S Hooker, J Adebayo, M Alber, K T Schütt, S Dähne, D Erhan, B Kim, W Samek, G Montavon, A Vedaldi, L K Hansen, 10.1007/978-3-030-28954-6_14Explainable AI: Interpreting, Explaining and Visualizing Deep Learning. K.-R Müller, Cham, SwitzerlandSpringer International Publishing2019</p>
<p>Efficient and enhanced sampling of drug-like chemical space for virtual screening and molecular design using modern machine learning methods. M Goel, R Aggarwal, B Sridharan, P K Pal, U D Priyakumar, 10.1002/wcms.1637Rev. Comput. Mol. Sci. 132023. e1637Wiley Interdiscip</p>
<p>The chemical space project. J L Reymond, 10.1021/ar500432kAcc. Chem. Res. 482015</p>
<p>Chemical space and biology. C M Dobson, 10.1038/nature03192Nature. 4322004</p>
<p>Exploring chemical space for drug discovery using the chemical universe database. J L Reymond, M Awale, 10.1021/cn3000422ACS Chem. Neurosci. 32012</p>
<p>Application of Fragment-Based Drug Discovery to Versatile Targets. Q Li, 10.3389/fmolb.2020.00180Front. Mol. Biosci. 71802020</p>
<p>Fragment-based approaches in drug discovery and chemical biology. D E Scott, A G Coyne, S A Hudson, C Abell, 10.1021/bi3005126Biochemistry. 512012</p>
<p>Ligand efficiency: A useful metric for lead selection. A L Hopkins, C R Groom, A Alex, Drug Discov. Today. 92004</p>
<p>Ligand efficiency indices as guideposts for drug discovery. C Abad-Zapatero, J T Metz, 10.1016/S1359-6446(05)03386-6Drug Discov. Today. 102005</p>
<p>Twenty years on: The impact of fragments on drug discovery. D A Erlanson, S W Fesik, R E Hubbard, W Jahnke, H Jhoti, 10.1038/nrd.2016.109Nat. Rev. Drug Discov. 152016</p>
<p>The rise of fragment-based drug discovery. C W Murray, D C Rees, 10.1038/nchem.217Nat. Chem. 12009</p>
<p>Efficient exploration of chemical space by fragment-based screening. R J Hall, P N Mortenson, C W Murray, 10.1016/j.pbiomolbio.2014.09.007Prog. Biophys. Mol. Biol. 1162014</p>
<p>NMR-Fragment Based Virtual Screening: A Brief Overview. M Singh, B Tam, B Akabayov, 10.3390/molecules23020233Molecules. 232332018</p>
<p>Artificial Intelligence's Impact on Drug Discovery and Development From Bench to Bedside. K S Vidhya, A Sultana, M Kumar, N Rangareddy, H , 10.7759/cureus.47486Cureus. 152023e47486. [CrossRef</p>
<p>Optimizing distributions over molecular space. An objective-reinforced generative adversarial network for inverse-design chemistry (ORGANIC. B Sanchez-Lengeling, C Outeiral, G L Guimaraes, A Aspuru-Guzik, 10.26434/chemrxiv.5309668.v32017</p>
<p>Aspuru-Guzik, A. Inverse molecular design using machine learning: Generative models for matter engineering. B Sanchez-Lengeling, 10.1126/science.aat2663Science. 3612018</p>
<p>New combined Inverse-QSAR and molecular docking method for scaffoldbased drug discovery. R Menacer, S Bouchekioua, S Meliani, N Belattar, 10.1016/j.compbiomed.2024.108992Comput. Biol. Med. 1802024. 108992</p>
<p>The rise of deep learning in drug discovery. H Chen, O Engkvist, Y Wang, M Olivecrona, T Blaschke, 10.1016/j.drudis.2018.01.039Drug Discov. Today. 232018</p>
<p>Molecular Sets (MOSES): A Benchmarking Platform for Molecular Generation Models. D Polykovskiy, A Zhebrak, B Sanchez-Lengeling, S Golovanov, O Tatanov, S Belyaev, R Kurbanov, A Artamonov, V Aladinskiy, M Veselov, 10.3389/fphar.2020.565644Front. Pharmacol. 112020</p>
<p>Benchmarking Models for de Novo Molecular Design. N Brown, M Fiscato, M H S Segler, A C Vaucher, Guacamol, 10.1021/acs.jcim.8b00839J. Chem. Inf. Model. 592019</p>
<p>Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions. P Ertl, A Schuffenhauer, 10.1186/1758-2946-1-8J. Cheminform. 12009</p>
<p>Retrosynthetic accessibility score (RAscore)-Rapid machine learned synthesizability classification from AI driven retrosynthetic planning. A Thakkar, V Chadimova, E J Bjerrum, O Engkvist, J L Reymond, 10.1039/D0SC05401AChem. Sci. 122021</p>
<p>MolFilterGAN: A progressively augmented generative adversarial network for triaging AI-designed molecules. X Liu, W Zhang, X Tong, F Zhong, Z Li, Z Xiong, J Xiong, X Wu, Z Fu, X Tan, 10.1186/s13321-023-00711-1J. Cheminform. 152023</p>
<p>Simpler is Better: How Linear Prediction Tasks Improve Transfer Learning in Chemical Autoencoders. N C Iovanac, B M Savoie, 10.1021/acs.jpca.0c00042J. Phys. Chem. A. 1242020</p>
<p>Automatic Chemical Design Using a Data-Driven Continuous Representation of Molecules. R Gomez-Bombarelli, J N Wei, D Duvenaud, J M Hernandez-Lobato, B Sanchez-Lengeling, D Sheberla, J Aguilera-Iparraguirre, T D Hirzel, R P Adams, A Aspuru-Guzik, 10.1021/acscentsci.7b00572ACS Cent. Sci. 42018</p>
<p>An Advanced Generative Adversarial Autoencoder Model for de Novo Generation of New Molecules with Desired Molecular Properties in Silico. A Kadurin, S Nikolenko, K Khrabrov, A Aliper, A Zhavoronkov, Drugan, 10.1021/acs.molpharmaceut.7b00346Mol. Pharm. 142017</p>
<p>Direct steering of de novo molecular generation with descriptor conditional recurrent neural networks. P C Kotsias, J Arús-Pous, H M Chen, O Engkvist, C Tyrchan, E J Bjerrum, 10.1038/s42256-020-0174-5Nat. Mach. Intell. 22020</p>
<p>Reusability report: Designing organic photoelectronic molecules with descriptor conditional recurrent neural networks. S Mohapatra, T Yang, R Gómez-Bombarelli, 10.1038/s42256-020-00268-wNat. Mach. Intell. 22020</p>
<p>Inverse molecule design with invertible neural networks as generative models. W Hu, J. Biomed. Sci. Eng. 142021</p>
<p>Drug discovery with explainable artificial intelligence. J Jiménez-Luna, F Grisoni, G Schneider, 10.1038/s42256-020-00236-4Nat. Mach. Intell. 22020</p>
<p>Overfitting, underfitting and general model overconfidence and under-performance pitfalls and best practices in machine learning and AI. C Aliferis, G Simon, 10.1007/978-3-031-39355-6_10Artificial Intelligence and Machine Learning in Health Care and Medical Sciences: Best Practices and Pitfalls. Cham, SwitzerlandSpringer2024</p>
<p>Ethical and Bias considerations in artificial intelligence (AI)/machine learning. M Hanna, L Pantanowitz, B Jackson, O Palmer, S Visweswaran, J Pantanowitz, M Deebajah, H Rashidi, 10.1016/j.modpat.2024.100686Mod. Pathol. 382024. 100686</p>
<p>Exploration of Ultralarge Compound Collections for Drug Discovery. W A Warr, M C Nicklaus, C A Nicolaou, M Rarey, 10.1021/acs.jcim.2c00224J. Chem. Inf. Model. 622022</p>
<p>M Krenn, Q Ai, S Barthel, N Carson, A Frei, N C Frey, P Friederich, T Gaudin, A A Gayle, K M Jablonka, 10.1016/j.patter.2022.100588SELFIES and the future of molecular string representations. Patterns 2022, 3, 100588. [CrossRef</p>
<p>Interpretation of QSAR models by coloring atoms according to changes in predicted activity: How robust is it?. R P Sheridan, 10.1021/acs.jcim.8b00825J. Chem. Inf. Model. 592019</p>
<p>Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods. instructions or products referred to in the content</p>            </div>
        </div>

    </div>
</body>
</html>